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Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis, 
are chronic diseases of the gastrointestinal tract. Genetic studies have identified strong 
association between genes involved in autophagy, ER-stress/unfolded protein response 
(UPR) and IBD. Stimulating autophagy may be beneficial for the treatment of IBD, and 
thiopurines, a class of drugs in clinical use for IBD, have been shown to induce autophagy. 
The aim of this study was to investigate the mechanism of action of thiopurines azathioprine 
(AZA), 6-MP and 6-TG in the context of autophagy, with focus on the interplay between 
autophagy and ER-stress/UPR signalling pathways. 
Methods 
Autophagy was evaluated by confocal fluorescence microscopy and live-cell imaging of 
autophagy marker LC3. Cell viability was assessed by Alamar Blue assay, and induction of 
apoptosis assessed by Annexin V/PI staining. Activation of ER stress and UPR signalling was 
investigated by reverse transcription polymerase chain reaction (RT-PCR), quantitative RT-
PCR (RT-qPCR) and immunoblotting. Modulation of mechanistic target of rapamycin 
(mTORC1) was assessed by immunoblotting.   
Results  
AZA, 6-MP and 6-TG are strong inducers of autophagy, with AZA inducing autophagy more 
rapidly than 6-MP or 6-TG. AZA and 6-TG increased early apoptosis, while 6-TG reduced cell 
viability and inhibited cell growth. Thiopurines did not induce ER stress, however, 6-TG 
activated the UPR pathway. AZA induced autophagy via mechanisms involving modulation of 
mTORC1 signalling. 
Conclusions 
Thiopurines are strong inducers of autophagy. There are differences in AZA, 6-MP and 6-TG 
mechanism of action, therefore, a better understanding may lead to personalised application, 
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Chapter 1. Introduction  
1.1. Inflammatory bowel disease  
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory condition that 
can affect all of the gastrointestinal (GI) tract and consists of two main forms known 
as Crohn’s disease (CD) and Ulcerative colitis (UC). As shown on Figure 1, UC 
commonly presents as mucosal inflammation that is limited to the colon whereas CD 
causes transmural inflammation that can affect the entire GI tract in a non-continuous 
manner, which can lead to complications such as fistulas, strictures and abscesses 
(Zhang and Li, 2014). Symptoms of IBD include weight loss, abdominal pain, diarrhoea 
and GI bleeding (Cummins and Crean, 2016).  Currently, 300,000 individuals suffer 
from IBD in the UK (Crohn’s & Colitis UK, 2018). With there being no cure for the 
disease, patients face years of medication, invasive colonoscopy surveillance and a 
high likelihood of surgery to mitigate symptoms and maintain remission (Shaw et al., 
2019). The average annual cost for IBD treatment in the UK is approximately £3000-
6000 per patient (Ghosh and Premchand, 2015). An NHS audit undertaken in 2010 
estimated an annual direct cost of more than £1 billion for the treatment and surgery 
associated with IBD (Ghosh and Premchand, 2015). IBD cases have risen 
dramatically by 85.1% since 1990, with the disease originally considered an issue 
particularly within westernised societies due to lifestyle, however it is now considered 
global disease issue (Alatab et al., 2020; Bernstein and Shanahan, 2008). The peak 
age of IBD occurrence is typically between the age of 15 to 35 years old, with up to 
10% of patients being under the age of 20, with IBD particularly effecting younger 
populations based within urbanised areas (M’Koma, 2013; Novak and Mollen, 2015). 
CD and UC are diagnosed through biopsy, endoscopy and other imaging methods, 
taking into consideration signs and symptoms present within the patient. Difficulties 
can arise when distinguishing CD and UC, in some cases patients will be diagnosed 
with intermediate colitis until defining features of CD and UC become present (Alatab 
et al., 2020). The aetiology is unknown, however it is thought to be an intricate 
relationship between environmental factors, genetic factors, and the intestinal 
microbiome that results in breakdown of epithelial barrier integrity and an inappropriate 
































Figure 1 - Crohn's disease and ulcerative colitis disease 
characteristics.  
Author’s illustration shows the main characteristics of CD and UC. Image created 
using Biorender software.  
Figure 2 - Factors associated with IBD pathogenesis. 
Three main factors are associated with IBD pathogenesis; environmental 
factors; genetic factors and the intestinal microbiome. All three factors are linked 
to breakdown of epithelial barrier integrity, which is a key event in IBD. Image 
created using Biorender software. 
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1.2. Intestinal microbiome 
The intestinal microbiota is composed of up to 1014 enteric microbes and 500 different 
bacterial species (Thursby and Juge, 2017). These microbes are essential in intestinal 
homeostasis by providing nutrients, regulating metabolism and aiding in the 
development of the immune system within the host (Thursby and Juge, 2017). 
Abnormal microbial ecology is a common characteristic found in IBD patients, known 
as dysbiosis. A reduction in abundance and diversity of bacteria in the gut is found in 
IBD, with a decreased abundance of phyla within Firmicutes and Bacterioides, and an 
increase in phylum such as Gammaproteobacteria. An increase in bacteria such as 
Enterobacteriaceae, Fusobacteriaceae and a decrease in Bacreroidales was strongly 
correlated with disease severity (Zuo and Ng, 2018). The reduction of bacterial 
diversity in the microbiota can allow opportunistic pathogens to thrive and initiate 
inflammation (Zuo and Ng, 2018). The opportunistic pathogen, adherent invasive 
Escherichia coli (AIEC), a member of the Enterobacteriaceae phyla, has been isolated 
in both UC and CD patients (Darfeuille-Michaud et al., 2004). AIEC can colonise on 
the intestinal epithelial barrier and invade the epithelial barrier through Peyer’s 
patches, where the earliest lesions of CD are observed (Rolhion and Darfeuille-
Michaud, 2007). Once they are intracellular, AIEC can persist and stimulate 
macrophages to produce excessive amounts of tumour necrosis factor-alpha (TNF-α), 
exacerbating inflammation (Bringer et al., 2012)  
Firmicutes and Bacteroidetes are predominant members of a healthy microbiota. A 
member of the Firmicute family, Faecalibacterium praunitizii is well characterised for 
its anti-inflammatory properties, and restoration of F.prausnititzii is associated with 
maintaining remission in UC patients (Rolhion and Darfeuille-Michaud, 2007). In 
addition to immune regulation by anti-inflammatory cytokines such as IL-10, Firmicutes 
also produce short chain fatty acids (SCFAs), which regulate metabolism in colonic 
epithelial cells and regulate immunity by assisting the proliferation of Treg cells (Smith 
et al., 2013; Venegas et al., 2019). SCFA’s also regulate the expression of host 
defence peptides, such as the cathelicidin LL-37, which help to prevent the expansion 
of pathogenic bacteria in the intestine due to their profound antimicrobial properties 




1.3. Environmental factors 
Environmental factors play a critical role on the onset of IBD, with epidemiology studies 
relating IBD pathogenesis with industrialisation and a westernised lifestyle 
(Ananthakrishnan et al., 2018). Risk factors associated with IBD include diet, antibiotic 
use, hygiene, infection and pollution; all with considerable amounts of evidence to 
suggest their potential for altering the microbiome (Ananthakrishnan et al., 2018). A 
popularised theory to explain the implications of environmental factors in IBD is the 
hygiene hypothesis. This hypothesis suggests that changes in the gut microbiota 
through factors such as antibiotics, dietary changes, and increases in sanitation, all 
found within westernised countries, leads to a loss of microbial diversity and 
consequently a loss of immunological tolerance (Abegunde et al., 2016). 
The use of antibiotics has been found to be effective in IBD patients, which is thought 
to be due to ability to reduce the burden of pathogenic bacteria in the microbiota 
(Abegunde et al., 2016). On the contrary, regular antibiotic use has been correlated 
with the on-set of IBD, potentially due the non-specific effects of antibiotics leading to 
the reduction of commensal bacteria and dysbiosis (Aniwan et al., 2018). Non-
steroidal anti-inflammatory drugs (NSAID) are also associated with CD activity, but not 
UC (Long et al., 2017). As well as NSAID’s, smoking appears to have contradicting 
effects in CD and UC, illustrating the complexity of both disease subtypes. Smoking is 
one of the most well studied factors in IBD and has been found to exacerbate 
inflammation in CD and be protective in UC patients (Ramos and Papadakis, 2019). 
Theories to explain this protective mechanism include the potential of nicotine to 
induce mucin synthesis, which is impaired in UC patients (Bastida and Beltrán, 2011).  
A high-fibre diet has been found to decrease CD risk by up to 40% (Ananthakrishnan 
et al., 2013). Whereas diets containing highly processed meats and high saturated 
fatty acids increase the risk of IBD (Ramos and Papadakis, 2019). Fibre is fermented 
in the large bowel by anaerobic bacteria that results in the production of the SCFA, 
butyrate, which influences microbiota composition, immune regulation and aids in 
intestinal barrier integrity by preventing the translocation of opportunistic pathogens 
such as AIEC across Peyer’s patches (De Filippo et al., 2010; Roberts et al., 2010; 
Vinolo et al., 2011). Ultraviolet light exposure based on geographical location has also 
been correlated with the incidences of IBD, with individuals exposed to less ultraviolet 
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light based in northern latitudes exhibiting an increased risk of IBD (Holmes et al., 
2015). The vitamin D receptor has major implications in IBD as it has been associated 
with immune regulation, nucleotide-binding oligomerization domain-containing 
protein 2 (NOD2) and autophagy signalling, all factors which have been directly linked 
to IBD pathogenesis (Verway, 2010). Vitamin D3 (1, 25(OH) D3) administration was 
associated within a decrease in TNF-α gene expression and colitis in mice models, 
illustrating the impact that Vitamin D3 deficiency could have on IBD patients  
(Abegunde et al., 2016). Therefore, the environmental factors discussed could lead to 
the dysregulation of the immune response and microbial dysbiosis, which can 
subsequently lead to breakdown of the intestinal barrier in a genetically susceptible 
host. 
1.4. Genetic factors associated with IBD 
Genetics plays a major role in the pathogenesis of IBD, with the latest genetic 
association study identifying 240 different susceptibility loci for IBD (De Lange et al., 
2017). Epidemiological studies illustrate that ~15% of CD patients have an affected 
family member and the concordance rate for monozygotic twins suffering from CD is 
50%, in contrast to dizygotic twins, which is less than 10% (Loddo and Romano, 2015). 
Although CD and UC exhibit distinct clinical characteristics, they share approximately 
30% IBD-associated genetic loci (Khor et al., 2011). However, genetic factors appear 
to have more significant implications in CD than UC, with a 26-fold increased risk for 
developing CD if a previous sibling suffers from the disease compared to UC which is 
a 9-fold increase (Uhlig et al., 2014). Of the multiple IBD susceptibility loci discovered, 
NOD2 and genes involved in autophagy signalling have the most significant 
association with IBD pathogenesis. 
1.4.1. NOD2 
In CD, NOD2 remains the strongest genetic determinant, with three NOD2 single 
nucleotide polymorphisms (SNPs) accounting for approximately 80% of CD 
associated variants; the  variants include 1007fs, R702W and G908R located within 
the leucine rich repeat (LRR) domain, important for recognition of the bacterial cell wall 
component muramyl dipeptide (MDP)  (Figure 3) (Parkhouse and Monie, 2015; Sidiq 
et al., 2016). Allele frequency studies have found that the insertion mutation, 1007fs, 
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which results in truncation of the LRR domain, was found in up to 8-16% of CD 
patients, compared to 2-4% in healthy control groups (Heliö et al., 2003). In addition, 
meta-analysis studies show that NOD2 homozygotes exhibit a 17.1-fold increase in 
CD development and 2.4-fold increase in NOD2 heterozygotes (Economou et al., 
2004).  
NOD2 is a member of the pattern recognition receptor (PRR) family of proteins. PRRs, 
such as Nod like receptors (NLRs) and Toll-like receptors (TLRs), are critical in the 
innate immune response as they recognise pathogen antigens (pathogen-associated 
molecular patterns (PAMPs)) or molecules released from damaged cells (Damage-
associated molecular patterns (DAMPs)) (Amarante-Mendes et al., 2018). NOD2 is 
highly expressed in Paneth cells located at the crypts of the small intestine and in 
myeloid lineages, including dendritic cells (DC) and macrophages (Eckmann and 
Karin, 2005). As shown on Figure 3, recognition of MDP by NOD2 promotes the 
oligomerisation and recruitment of RIP2, which allows the recruitment of TRAF2, 
TRAF6 and cIAP2. TRAF-6 recruitment leads to the activation of mitogen-activated 
protein kinases (MAPK) including p38 and ERK (Kobayashi et al., 2005). In addition, 
recruitment allows the ubiquitination of the NF-κB essential modulator (NEMO) and 
can activate NF-kB, through the activation of IκB kinase complex (IKK) and 
phosphorylation of IκBα (Negroni et al., 2018). Both the activation NF-kB and MAPK 
leads to production of a range of cytokines and host-defence peptides, including TNF-
α, IL-1β, IL-10, IL-8 and a-defensins (Sidiq et al., 2016). NOD2 variants have been 
found to have impaired NF-kB production in the presence of bacterial 
lipopolysaccharide (LPS) and a reduction alpha-defensins 5 (HD5) and HD6 synthesis 
in Paneth cells of CD patients (Tan et al., 2015). This illustrates the importance of 
functional NOD2 signalling in bacterial sensing and immune regulation, two factors 




Figure 3 - NOD2 signalling in response to bacterial invasion. 
Authors illustration of NOD2 signalling and CD-associated NOD2 variants. (1) Internalisation of bacterial 
derived-MDP fragments through multiple routes including phagocytosis, endocytosis and membrane 
bound channels. (2) SLC15A43 and SLC15A4 release MDP fragments from endosomes into cytoplasm 
of cell. (3) LRR domain recognises MDP and initiates NOD2 signalling, allowing movement of ATG16L1 
to site of bacterial entry to subsequently activate autophagy. (4) Recognition of MDP allows 
oligomerisation and activation of RIP2. (5) TRAF6, TRAF2 and cIAP2 are recruited to the NOD2-RIP2 
complex. MAPK’s such as p38 and ERK are activated in a TRAF-6 dependent manner, which 
subsequently activate autophagy and pro-inflammatory cytokine signalling. (6) NEMO and TAK1 form 
a complex which subsequently activates IKK signalling. (7) phosphorylation of Iκα by IKK begins 
releases IκBα from NF-κB. (8) NF-κB translocates to the nucleus and upregulates pro-inflammatory 









1.4.2. Innate immunity and the role of macrophages in IBD  
The innate immune system is an evolutionary conserved response in mammals, which 
functions as the first line of defence against pathogens attempting to invade barrier 
surfaces, including the skin, respiratory and GI (Corridoni et al., 2018; Gasteiger et al., 
2017). Compared to adaptive immunity, innate immunity can be triggered more rapidly, 
lacking immunological memory, through the activation of PRR’s. Once activated, 
innate immune cells utilise cell-mediated mechanisms such as phagocytosis, 
cytotoxicity or secretary molecules such as host defence peptides, cytokines and 
complement factors to neutralise pathogens (Gasteiger et al., 2017). Innate immune 
cells, such as macrophages and DC’s, reside within the lamina propria of the intestinal 
epithelium and are responsible for the rapid discrimination of self and non-self-
antigens that are sampled from the gut lumen via M-cells located in the gut-associated 
lymphoid tissue (Ahluwalia et al., 2018). Macrophages and DC’s are also a key 
component in the crosstalk between the innate and adaptive immune system as they 
are well established antigen-presenting cells, which regulate lymphocyte proliferation 
through the presentation of antigens in major histocompatibility class (MHC) II proteins 
(Gaudino and Kumar, 2019).  
As shown on Table 1, intestinal resident macrophages differ from other tissue resident 
macrophages. It is thought that most tissue macrophages derive from an embryonic 
and haematopoietic precursor that have little replenishment by blood-derived 
monocytes (Yona et al., 2013). In contrast, intestinal macrophages are replenished by 
blood-derived monocytes throughout childhood (Na et al., 2019). It is still under debate 
exactly which sub-populations of macrophages reside in intestinal tissue, however, it 
is believed to contain a heterogenous population of macrophages that are functionally 
distinct (De Schepper et al., 2018). For example, in a mouse model, it was discovered 
two separate populations of macrophages exist that are transcriptionally different. 
These included TIM4- CD4- macrophages that were blood-derived monocyte 
dependent, and long-lived, tissue resident, TIM4+ CD4+ macrophages that were blood 
derived-monocyte independent (Shaw et al., 2018). It has also been shown that the 
gut contains the largest pool of tissue resident macrophages in the body (Nakanishi et 
al., 2015). Intestinal-resident macrophages display a more immune regulatory, anergic 
phenotype due to their proximity to the gut microbiome (Rubio and Schmidt, 2018). 
Intestinal resident macrophages have a downregulation of receptors for LPS (CD14), 
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IL-2, IL-3, and complement factors C3 and C4 compared to blood monocytes from the 
same donor (Smythies et al., 2005). They have a downregulation in the production of 
proinflammatory cytokines associated with TLR ligands, such as TNFα, IL-1 and IL-6, 
and instead have increased bactericidal activity through increased phagocytic 
capabilities (Smythies et al., 2005). They also maintain homeostasis in the gut through 
the production of anti-inflammatory ligands such as IL-10 and prostaglandin E2 (Platt 
et al., 2010). The downregulation of pro-inflammatory cytokines in intestinal-resident 
macrophages was found to be regulated by TGF-β, a cytokine produced in intestinal 
epithelial cells, which highlights the crosstalk between the two cell types (Smythies et 
al., 2005). Crosstalk between the intestinal epithelium and the immune system has 
also been highlighted by work from Courth et al., (2015), which illustrated ligands from 
the peripheral blood mononuclear cell (PBMC) secretome, such as Wnt ligands, aided 
in the formation HD5 and HD6 in Paneth cells, which could not be induced by 
independent factors such as cytokines and infections. 
Studies have illustrated an imbalance in homeostatic macrophage populations during 
colitis, with proinflammatory-blood derived monocytes (CD14+) being recruited within 
the lamina propria and a lack of expansion of regulatory tissue resident macrophages 
(Bain et al., 2013). Human biopsies from active IBD patients have also been shown to 
have an elevation in chemokine expression that promotes monocyte recruitment, 
including CCL7 and CCL8 (Bain et al., 2013). In addition, CD-associated monocytes 
exhibit a reduced production in Wnt ligands, suggesting an impairment in immune cell 
function that in turn can lead to Paneth cell dysfunction, due to the lack of Wnt-
associated receptor activation (Courth et al., 2015). A decrease in granulocyte-
macrophage colony-stimulating factor (GM-CSF) signalling activity, a ligand that 
promotes the differentiation of monocyte into regulatory macrophages, has been found 
to increase the risk of CD (Lotfi et al., 2019). An increase in GM-CSF specific 
autoantibodies and a decrease in the expression of CD116, a receptor specific to the 
GM-CSF ligand, on blood-derived monocytes has been observed in the serum of CD 
patients (Däbritz, 2015). Monocyte-derived macrophages (MDM) from CD patients are 
also more susceptible to infection with AIEC and persistent replication compared to 
MDM’s from healthy controls and UC patients (Vazeille et al., 2015). AIEC persistency 
is commonly found in CD patients, which can cause chronic inflammation due to their 
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ability to invade epithelial cells and induce a TH17-associated proinflammatory 
response (Small et al., 2013) 
 
Table 1 - Differences between blood-derived and intestinal-derived 
macrophages 
Blood-Derived Macrophages Intestinal-Resident Macrophages 
TIM4- CD4-  TIM4+ CD4+ 
High expression of innate response receptors  
(CD14, CD89, CD11b) 
Reduced expression costimulatory molecules (CD40, 
CD80 and CD86)  
Increased expression of chemokine receptor CX3CR1  
Phagocytic activity leading to immune cell 
activation 
Increased phagocytic activity without subsequent 
immune activation 
Hyper-responsive to pathogen stimuli Hypo-responsive to pathogen stimuli 
High expression of TREM-1 leading to increased 
pro-inflammatory mediators  
(TNF-a, IL-1β, IL-6) 
Absence of TREM-1 
High Pro-inflammatory cytokine production in 
response to PRR activation (TNF-α, IL-1β, IL-6 and 
nitric oxide) 
Production of anti-inflammatory cytokines IL-10 and 
TGF-β 
 
1.4.3. Autophagy genes associated with CD 
CD-associated SNPs have been identified within autophagy-related genes, including 
autophagy-related protein 16-1 (ATG16L1) and immunity-related GTPase family 
protein M (IRGM) (Massey & Parkes, 2008). Autophagy regulates multiple aspects of 
intestinal homeostasis ranging from bacterial clearance, antigen presentation, goblet 
cell function and host defence peptide production within Paneth cells, all of which can 
be impaired in IBD (El-Khider and McDonald, 2016). Impairment in the function of 
ATG16L1 allows the growth and persistency of opportunistic pathogens, AIEC and 
Mycobacterium avium paratuberculosis in macrophages, pathogens that have been 
speculated to trigger IBD-associated inflammation (Lapaquette et al., 2012; McNees 
et al., 2015).  The ATG16L1 T300A variant associated with autophagy dysfunction is 
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found in up to 30% of CD patients (Hampe et al., 2007). In addition, the ATG16L1 
T300A variant increases the susceptibility for disease risk by 3-fold in paediatric 
patients (Salem et al., 2015)  
SNPs associated with ATG16L1 have been found to impact the unfolded protein 
response (UPR) to endoplasmic reticulum (ER) stress. SNPs within the UPR-
associated genes, XBP1 and ORMDL3, have been identified as risk factors for IBD 
(Kaser et al., 2008). Interestingly, an increase in autophagy is observed in XBP1 -/- 
mice, which correlated with increased presence of ER stress markers including 
phosphorylation of eif2α and ATF4 (Adolph et al., 2013). The increased presence of 
proteins associated with ER stress was also found in the intestinal mucosa of IBD 
patients and healthy controls harbouring the ATG16L1 T300A variant, indicating the 
importance of functional autophagy within UPR/ER stress signalling (El-Khider and 
McDonald, 2016). These studies provide evidence that CD-associated polymorphisms 
regulate autophagy activity, and that autophagy is a key mechanism utilised by other 
pathways implicated in CD pathogenesis such as the ER-stress/UPR. 
 
1.4.4. Autophagy 
Macro-autophagy (referred henceforth as ‘autophagy’) is an evolutionarily conserved 
homeostatic lysosomal degradation pathway that involves the degradation and 
recycling of cellular constituents that range from misfolded proteins to damaged 
organelles through the use of a unique double membrane-bound vesicle, known as an 
autophagosome (Fritz et al., 2011). Physiologically, its function regulates cell 
remodelling and prevents premature cell aging through the degradation of damaged 
proteins and organelles. Autophagy functions at a basal level to maintain homeostasis 
within protein and organelle turnover. However, it can also be induced as a survival 
response through the presence of stress stimuli such as hypoxia, starvation and 
infection (King, et al., 2011). The stimulation of autophagy as a survival response was 
first characterised in yeast by Ohsumi and colleagues who observed the gradual 
increase of spherical bodies, which were termed autophagic bodies, when grown in a 
nutrient deprived media (Takeshige et al., 1992) . Autophagy is activated in response 
to multiple physiological stresses including hypoxia, nutrient deficiency, cellular toxins 
and pathogen invasion (Badadani, 2012). Autophagy regulates a diverse range of 
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cellular processes, including cell fate, growth, oxidative stress, organelle turnover and 
cell differentiation (Badadani, 2012). Due to the wide range of physiological roles that 
autophagy is involved in, it has been linked to the pathophysiology of a growing 
number of diseases in addition to IBD, including cancer, neurodegenerative diseases, 
infectious diseases and metabolic diseases such as type 2 diabetes (Jiang and 
Mizushima, 2014)  
 
1.4.5. The autophagy pathway 
Autophagy performs its homeostatic function by encapsulating target constituents 
(cargo) in a vesicle termed an autophagosome, which is then able to fuse with a 
lysosome to form an autophagolysosome where cargo are degraded by lysosomal 
proteases (Wong et al., 2011). As illustrated in Figure 4, autophagosome formation 
can be split into four distinct steps. These are the initiation and encapsulation of cargo 
within a double membrane called a phagophore, the maturation of the phagophore to 
form an autophagosome, the fusion of a lysosome to form an autophagolysosome and 
finally the degradation of the cargo within the autophagolysosome (Moulis and Vindis, 
2017).  
The process of autophagy is regulated by the intricate interaction between autophagy 
related (Atg) proteins. The role of various Atg proteins have been extensively reviewed 
(Klionsky, 2005; Yorimitsu and Klionsky, 2005), however, this study will primarily focus 
on the importance of ATG16L1 and Atg8 (also known as LC3 in its mammalian 
ortholog) during autophagy. Two distinct ubiquitin-like conjugation systems are crucial 
for the extension and sealing of the autophagosomal membrane, these two 
conjugation systems are the Atg12 conjugation system and the LC3 conjugation 
system (El-Khider and McDonald, 2016). The Atg12 conjugation system involves the 
recruitment of the ATG12-ATG5-ATG16L1 complex, which begins with the 
conjugation of Atg12 to Atg5 that is catalysed by both Atg7 and Atg10 (Ohsumi and 
Mizushima, 2004). During this event, the LC3 conjugation system is activated 
beginning with the processing of proLC3 by the cysteine protease, ATG4, to expose 
its carboxyl terminal glycine that creates the cytosolic form of LC3, LC3-I (Tanida et 
al., 2004). In nutrient rich conditions, LC3-I is widely distributed across the cytoplasm 
and nucleus (Ladoire et al., 2012). However, when autophagy is stimulated such as 
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during starvation, LC3 becomes redistributed where nuclear LC3 congregates within 
the cytoplasm through the deacetylation of LC3 by Sirt1 (Lee and Lee, 2016). Once 
LC3 is accumulated in the cytosol, ATG7 and ATG3 are activated, which allows the 
formation of an ATG3-LC3 intermediate (Ohsumi and Mizushima, 2004). This 
intermediate interacts with ATG12 within the ATG12-ATG5-ATG16L1 complex 
through ATG3 and allows the recruitment of the ATG3-LC3 to the infant 
autophagosome membrane, which causes LC3 to become conjugated to 
phosphatidylethanolamine (PE) (Fujita et al., 2008). The conjugation of LC3 to PE 
defines the transformation of LC3-I to LC3-II and allows the anchoring of the substrate 
to the autophagosomal membrane. LC3 is thought to be involved in the expansion and 
closure of the autophagosomal membrane (Lapaquette et al., 2015). LC3-II is also 
critical for selective autophagy as specific autophagy cargo receptors such as p62, 
NBR1 and NDP52 contain LC3-interacting regions (LIR) that are able to bind to LC3 
and allow the cargo to undergo degradation (Hansen and Johansen, 2011). Most of 
the ATG proteins are only found on the isolation membranes but not on the 
autophagosomes themselves, only LC3 has been found to be fused to the 
autophagosome throughout the autophagy process. LC3 is removed from the 
autophagosomal membrane at the end of the process during the fusion of the 
lysosome, where it either is cleaved from the outer membrane by Atg4 for re-use or is 
degraded on the inner membrane through lysosomal enzymes. This therefore allows 









Figure 4 - Autophagosome formation.  
Author’s illustration of the molecular mechanisms within autophagosome formation 1. Dissociation of 
mTORC1 from ULK1/2-ATG13-FIP200 complex due to the presence of stress stimuli 2. ULK complex 
activates Beclin1-ATG14-VPS34-VPS15 complex on the ER surface. VPS34 (teal) marks the area of 
phagophore formation (omegasome) 3. VPS34 synthesises PI3P that accumulates (Black) and is 
recognised by WIPI and DFCP1 that allows the recruitment of ATG12-ATG5-ATG16L1 complex 4. 
Cytosolic LC3-I is converted to LC3-PE through the interaction with ATG12 within the ATG12-ATG3-
ATG16L1 complex. LC3-PE conjugation allows it to be anchored to the autophagosomal membrane 5. 
Omegasome becomes detached from the ER to form a phagophore in which LC3-II (green) covers both 
the outer and inner membrane. LC3 is involved in the expansion and closure of the membrane. LC3 is 
also involved in the anchoring of specific cargo within the membrane through the interaction with LIR 
on constituents. 6. Full closure of the phagophore results in the formation of the autophagosome, a 
vesicle that encapsulates constituents preparing them for degradation 7. The lysosome binds to the 
autophagosome releasing lysozymes that degrade the constituents. LC3 on the outer membrane is 
removed through the interaction with ATG4 to be recycled and LC3 within the inner membrane is 
degraded along with the constituents. 
 
1.4.6. Autophagy Signalling 
The regulation of autophagy in response to stress stimuli primarily involves signalling 
through mammalian target of rapamycin complex 1 (mTORC1) and AMP-activated 
protein kinase (AMPK) (El-Khider and McDonald, 2016). The initiation of autophagy 
utilises two specific protein kinases, which are the ULK1/2-ATG13-FIP200 complex 
and the Beclin1-Vps34-Vps15-ATG14 complex that are regulated through interactions 
with mTORC1 and Bcl2, respectively. In nutrient rich conditions, the mTORC1 
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complex is bound to the ULK1/2-ATG13-FIP200 complex and inhibits ULK1/2 kinase 
activity through the phosphorylation of ULK1/2 and ATG13 (Lapaquette et al., 2015). 
AMPK under physiological conditions is inhibited due to the high concentrations of 
ATP within the cell (El-Khider and McDonald, 2016). However, once the cell is 
exposed to a stress stimuli, the mTORC1 complex becomes inactive through AMPK 
(in the presence of increased intracellular AMP production) and allows the dissociation 
of the ULK complex (Pezze et al., 2016). This allows the ULK complex to recruit and 
activate the Beclin1-ATG14-Vps34-Vps15 complex to the membrane that is marked 
by ATG9, subsequently allowing the recruitment of ATG proteins such as ATG16L1 
and LC3 and the induction of phagophore formation (Lamb et al., 2013; Lapaquette et 
al., 2015). Specifically, Vps34, a class III phosphatidylinositol 3-kinase, marks the area 
in which phagophore develops from the ER through the formation of a structure called 
an omegasome, a pre-phagophore structure which is rich in PI3P (Axe et al., 2008). 
The accumulation of PI3P by the formation of the omegasome  is recognised through 
effector molecules such as DFCP1 and WIPI that allows the important recruitment of 
the ATG12-ATG5-ATG16L1 complex, which is crucial for the elongation process 
(Devereaux et al., 2013; Lapaquette et al., 2015). The ER is well regarded as a major 
organelle for autophagosome biogenesis (Karanasios et al., 2013). However other, 
sources have been implicated in autophagosome biogenesis including the 
mitochondria, plasma membrane and the Golgi apparatus (Hailey et al., 2010; Geng 
et al.,2010; Ravikumar et al., 2011). For example, the mitochondria and ER have been 
found to communicate through mitochondria-associated membranes (MAMs), and 
disruption of MAMs leads to an impairment of autophagosome formation during 
starvation (Hamasaki et al., 2013). This is thought to be due to MAMs assisting the 
production of ATG4 and STX17, major proteins in autophagosome closure and some 
have speculated that MAMs are the site of origin for autophagosome formation 
(Hamasaki et al., 2013; Tsuboyama et al., 2016) 
1.4.7. Intersection of NOD2 and autophagy in IBD 
NOD2 has been shown to functionally intersect with ATG16L1, with NOD2 recruiting 
ATG16L1 to the plasma membrane during bacterial infection (Travassos et al., 2010). 
Interestingly, in the presence of the 1007fs mutation found in NOD2, ATG16L1 does 
not localise to the plasma membrane during bacterial invasion (Travassos et al., 
2010). Triggering of other functional PRR’s, which have been known to induce 
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autophagy, could not compensate for the impairment in the NOD2-ATG16L1 signalling 
axis, leading to increased bacterial burden in the cell (Cooney et al., 2010) CD-
associated DC’s that harbour NOD2 variants were found to have a significant increase 
in bacterial persistency when infected with AIEC, which could be reversed when 
treated with the autophagy inducer, rapamycin (Cooney et al., 2010). Silencing of 
autophagy-related genes also resulted in a decrease in MHC II surface expression 
and antigen presentation within DC’s (Cooney et al., 2010). NOD2 has also been 
associated with Paneth cell phenotype; patients containing one or more NOD2 
susceptibility alleles exhibit an increase in Paneth cell abnormalities compared to 
individuals with wild type NOD2. The frequency of Paneth cell abnormalities is further 
increased in individuals containing both the NOD2 and ATG16L1 T300A variant 
(Vandussen et al., 2014). Therefore, impaired bacterial handling and immune priming 
caused by defective autophagy, through genetic factors, may be a key inducer of CD-
associated inflammation. 
1.4.8. Intestinal barrier integrity 
SNP’s have also been identified in genes associated with intestinal epithelial barrier 
integrity, such as CDH1, and genes associated with mucus production such as AGR2 
and MUC2 (Antoni et al., 2014; McCole, 2014). MUC2 is a critical gene associated 
with mucin production by intestinal goblet cells, which coats the outer epithelial surface 
and reduces the rate of invasion and colonisation of bacteria on the mucosa surface 
(Kim and Cheon, 2017; Van der Sluis et al., 2006). Interestingly, missense mutations 
within MUC2 resulted in mice developing spontaneous distal intestinal inflammation, 
which was similar to the phenotype observed within UC (Heazlewood et al., 2008). 
AGR2 regulates the disulphide bond formation in proteins present in the ER (Park et 
al., 2009). AGR2 has also been found to be decreased in CD and UC patients (Zheng 
et al., 2006). Due to the high expression of AGR2 in Paneth cells and goblet cells, 
AGR2 -/- mice exhibit abnormalities such as decrease in mucus production, a 
reduction in goblet cells, dysfunctional Paneth cells and spontaneous colitis (Zhao et 
al., 2010) 
1.4.9. Epithelial Barrier Integrity in IBD 
Intestinal epithelium integrity regulates the interaction of the microbiota and immune 
cells within the lamina propria, allowing restricted passage of small amounts of 
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bacteria for antigen sampling and immune surveillance (Slack et al., 2009). As shown 
in Figure 5, increased intestinal epithelial permeability allows an influx of pathogens, 
toxins and food antigens to initiate an inflammatory response, which is thought to be 
one of the underlying mechanisms for IBD pathogenesis (Kim and Cheon, 2017) A 
breakdown of epithelial barrier integrity, through double negative mutations within N-
cadherin (involved in calcium-dependent cell to cell adhesion) has been found to 
develop IBD-like ileitis in mice highlighting the importance of epithelial barrier integrity 
in IBD (Hermiston and Gordon, 1995). In addition, total regeneration of the intestinal 
epithelial barrier, which has been termed mucosal healing, increases the likelihood of 
long-term remission and a reduced need for surgical treatment in IBD patients. 
(Okamoto and Watanabe, 2016). 
Interestingly, mutations in genes directly linked to epithelial barrier integrity, such as 
MUC2, result in spontaneous colitis in murine models. In contrast, mutations in genes 
that are not directly associated with intestinal epithelium result in an increased 
susceptibility to dextran sodium sulphate (DSS) induced colitis (Hooper et al., 2019). 
For example, the L1007fs mutation in NOD2 and LRRK2 deficiency, which regulates 
immune signalling, were found to increase susceptibility to DSS-induced colitis (Liu et 
al., 2011; Maeda et al., 2005). IBD-associated colitis is only initiated with these factors 
in the presence of chemical inducers of colitis, such as DSS, which substitutes 
environmental triggers of IBD including intestinal bacteria, viruses, dietary antigens 
and reactive oxygen species (ROS) (Heazlewood et al., 2008). The importance of 
epithelial barrier integrity is supported by studies that show deletion of ATG16L1 in 
intestinal epithelial cells (IEC) develop spontaneous ileitis (Tschurtschenthaler et al., 
2017). However, deletion of ATG16L1 in hematopoietic cells enhances susceptibility 
to DSS-induced intestinal barrier disruption in mice (Saitoh et al., 2008; 
Tschurtschenthaler et al., 2017). These findings suggest that the breakdown of the 
intestinal epithelium is the key initiator of IBD-associated colitis, and mutations not 
directly associated with the intestinal epithelium increase susceptibility and require an 
environmental trigger to initiate epithelium barrier breakdown. 
1.4.10. Composition of the intestinal epithelial barrier  
Specialised intestinal epithelial cells such as Paneth Cells and goblet cells, have been 
linked to IBD pathogenesis (Kim and Cheon, 2017). A reduction in goblet cells and 
31 
 
mucus production is a common pathological finding in IBD patients (Van der Sluis et 
al., 2006). MUC2 has also been found to be deficient in UC patients and correlated 
with disease severity (Larsson et al., 2011). In addition to mucus secretion, goblet cells 
depletion may impact in mucosal immunity as they are the primary producers of IL-7 
in the colonic mucosa (Oshima et al., 2004; Watanabe et al., 1998). IL-7 is a pleotropic 
cytokine that regulates the proliferation of mature and immature T cell lineages. IL-7 
has been found to selectively regulate effector T-cell migration to the gut through the 
regulation a α4β7 integrin expression (Belarif et al., 2019). IL-7 has also been found to 
be deficient in the serum of untreated CD patients compared to treated patients 
(Andreu-Ballester et al., 2013). Therefore, there is supporting evidence to suggest that 
intestinal epithelial cells aid in regulation of mucosal immunity.     
Paneth cells are another epithelial cell lineage that have been closely associated with 
IBD pathogenesis. As shown on Figure 5, Paneth cells are located in the crypts of the 
lumen and maintain intestinal homeostasis through the secretion of host defence 
peptides such as α-defensins and RegIIIγ (Wilson et al., 1999). Research on Paneth 
cell function is limited by the fact that there are no available cell lines derived from 
Paneth cell lineages (Courth et al., 2015). Furthermore, cell lines, such as colon 
cancer cell lines, often contain mutations in the Wnt pathway, a pathway heavily linked 
with defensin production and secretion (Courth et al., 2015). The importance of Paneth 
cell function in intestinal homeostasis is supported by findings that deletion of Mmp7, 
a metalloprotease involved in the processing of α-defensins, results in increased 
susceptibility to salmonella typhimurium infection in the intestinal mucosa (Wilson et 
al., 1999). Paneth cell dysfunction has also been found to regulate microbiota 
composition, with a reduction in anti-inflammatory associated bacterium including 
Faecalibacterium and an increase in pro-inflammatory bacterium Erysipelotrichacae 
found within paediatric CD patients (Vandussen et al., 2014). A common characteristic 
found in ileal CD patients is a reduction in the secretion of HD5 and HD6, indicating 
an impairment in Paneth cell function (Courth et al., 2015). Interestingly, researchers 
such as Adolph et al., (2013) have provided evidence to suggest that the inflammation 
observed in CD originates from Paneth cells, with dysfunction in Paneth cells leading 
to transmural inflammation in the form of skip lesions seen in CD. In addition, Paneth 
cells abnormalities have been directly correlated with granuloma formation, a common 
characteristic of CD-associated inflammation (Vandussen et al., 2014). Researchers 
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have also proposed Paneth cell abnormalities as a possible molecular biomarker for 
disease severity, by grouping patients with the presence of CD susceptibility loci, 
which has been associated with immune activation, a reduction in Paneth cell 


























Figure 5 - Intestinal Epithelial Barrier during IBD.  
Author’s representation of the association of the intestinal epithelial barrier during the pathogenesis of 
IBD. The diagram above represents the healthy mucosal layer in which the intestinal epithelial barrier 
is intact and successfully separating the microbiome and the effector cells within the lamina propria. It 
achieves this through the production of mucus by goblet cells and the production of host defence 
peptides by Paneth cells within the crypts of Lieberkühn. The bottom diagram illustrates the intestinal 
epithelial barrier during IBD where barrier integrity is lost through multiple factors. One crucial factor, 
as shown in bold, is the dysfunction in Paneth cells that leads to a loss of HDP (AMP) production, 





1.5. ER Stress 
The ER is a complex organelle mainly responsible for the synthesis, folding and 
movement of proteins, phospholipids and steroids across the cell (Schröder and 
Kaufman, 2005). The ER also contains the largest storage of calcium ions in the cell 
and regulates calcium concentrations through sarcoplasmic/endoplasmic reticulum 
calcium-ATPases and inositolo 1,4,5-triphosphate receptors that pump calcium 
between the cytoplasm and ER (Corazzari et al., 2017; Schröder and Kaufman, 2005). 
Calcium plays a critical role in cell metabolism, muscle contraction and apoptosis. In 
addition, many post-translational modifications, such as glycosylation, are calcium-
dependent (Schröder and Kaufman, 2005). Many external insults can disturb the 
homeostatic balance between the accumulation and breakdown of proteins in the ER, 
these include hypoxia, nutrient starvation, infection and xenobiotics (Walczak et al., 
2019). These factors can increase workload in the ER and lead to an accumulation of 
misfolded and unfolded proteins within the cell, known as ER stress. Sustained ER 
stress in the cell will lead to the activation of cell-death associated pathways and the 
initiation of apoptosis for the removal of compromised cells (Sano and Reed, 2013).  
1.6. The Unfolded Protein Response 
Eukaryotes have developed an adaptive mechanism to resolve ER-stress and 
maintain homeostasis and cell survival, this mechanism is known as the UPR 
(Chakrabarti et al., 2011). The UPR resolves ER stress by halting global protein 
synthesis, directing misfolded proteins to the ER-associated degradation (ERAD) 
pathway and increasing the folding capacity within the ER through membrane 
expansion and the synthesis of chaperone proteins (Cao and Kaufman, 2012). ERAD 
is separated into two subtypes, known as type 1 ERAD and type 2 ERAD. Type 1 
ERAD involves the retro translocation of misfolded proteins through the ER membrane 
to the cytosol where they undergo ubiquitination and degradation through 26S 
proteasomes (Hampton, 2002). Type 2 ERAD is autophagy dependent, which targets 
insoluble forms of misfolded proteins which cannot be degraded by type 1 ERAD 
(Rashid et al., 2015). Autophagy was initially proposed to be induced only when 
misfolded proteins become too excessive for ERAD to degrade (Rashid et al., 2015). 
However, Houck et al., (2015) has found that both types of ERAD are activated 
simultaneously, where type 2 ERAD eliminates soluble ERAD-resistant misfolded 
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proteins, including aggregated proteins unable to enter the proteolytic chamber within 
the proteasome. As shown in Figure 6, the UPR consists of three main signalling 
pathways, inositol-requiring enzyme 1 (IRE1) pathway, double-stranded RNA-
activated protein kinase (PKR)-like kinase (PERK) pathway and the activation 
transcription factor 6 (ATF6) pathway (Chakrabarti et al., 2011). IRE1, PERK and 
ATF6 are ER-resident transmembrane receptors which sense misfolded proteins 
through their luminal domain (LD) present on each receptor (Carrara et al., 2013). BiP 
(GRP78) is one of the most abundant chaperone proteins within the ER and assists in 
protein folding by preventing aggregation of polypeptide chains during the adolescent 
stages of protein folding (Adams et al., 2019). The function of BiP during the regulation 
of UPR signalling has been debated in depth elsewhere (Adams et al., 2019). 
However, it is widely accepted that BiP plays a sequestering role within IRE1, PERK 
and ATF6, which binds to the LD of each receptor preventing dimerization and the 
activation downstream signalling events in normal ER homeostasis (Adams et al., 
2019).  
1.6.1. IRE1 signalling  
During ER stress, BiP becomes dissociated from each of the membrane embedded 
UPR sensors, regulating the activation of downstream UPR signalling (Gardner et al., 
2013). IRE1 is the most conserved UPR sensor and is found in mammals, yeast and 
metazoans (Chen and Brandizzi, 2013). As a consequence of BiP dissociation, 
oligomerisation of IRE1 occurs, which allows the activation of the endoribonuclease 
effector domain that is present on IRE1 (Sidrauski and Walter, 1997). An increase in 
endonuclease activity leads to the splicing of 26 nucleotides from X-box binding 
protein 1 (XBP1) to a form a potent transcription factor, spliced XBP1 (XBP1s) (Adams 
et al., 2019). XBP1s contains a C-terminal transactivation domain and can translocate 
to the nucleus to upregulate the transcription of UPR-associated genes including those 
involved in ER biogenesis, ERAD, and protein folding (Wu et al., 2015). An increase 
in endonuclease activity also induces a process known as regulated IRE1-dependent 
decay (RIDD), where there is an increase in the degradation of ER membrane-
localised mRNA, leading to a reduction in protein synthesis (Hollien and Weissmann, 
2006). Cell fate will also be determined through the IRE1 pathway, which will initiate 
apoptosis through the selective degradation of UPR-associated genes by RIDD that 
will increase ER stress within the cell, driving apoptotic signalling (Chen and Brandizzi, 
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2013). RIDD will also increase apoptotic signalling through the degradation of anti-
apoptotic microRNAs such as anti-Casp2, allowing the upregulation of the pro-
apoptotic marker, caspase-2 (Upton et al., 2013). 
1.6.2. PERK pathway 
Dissociation of BiP from PERK leads to the autophosphorylation and dimerization of 
the receptor (Chakrabarti et al., 2011). Activation of PERK leads to the downstream 
phosphorylation of the α subunit (S51) within eukaryotic translation initiation factor 2α 
(eif2α) (Gebauer and Hentze, 2004). Eif2α is a vital component in protein translation 
initiation, therefore phosphorylation prevents the separation of eIF2α from eIF2B, thus 
preventing global translation initiation (Gebauer and Hentze, 2004). In combination to 
protein translation inhibition, PERK leads to the increase in pro-survival genes such 
as cellular inhibitor of apoptosis (cIAP), maintaining cell survival (Hamanaka et al., 
2009). Genes containing an internal ribosome entry site sequence in their 5’ 
untranslated region will be protected from translation inhibition, the most well-
established of these genes is ATF4 (Schröder and Kaufman, 2005). ATF4 plays both 
a pro-survival and pro-apoptotic role in the UPR. ATF4 can induce a pro-survival 
response by regulating protein secretion and amino acid transport, however, ATF4 
can also induce the expression of pro-apoptotic genes, including C/EBP homologous 
protein (CHOP) (Harding et al., 2000). Sustained activation of CHOP will lead to the 
induction of apoptosis by the repression of Bcl-2, which is negatively correlated with 
CHOP expression (Wei et al., 2008). 
1.6.3. ATF6 pathway 
ATF6 is similar to IRE1 and PERK, where activation is regulated through the 
dissociation of BiP, which is thought to be regulated by N-terminal Golgi localization 
sequences in ATF6 (Chakrabarti et al., 2011). However, ATF6 is unique to PERK and 
IRE1 as it not activated through the phosphorylation of its C-terminal kinase domain. 
Instead, ATF6 translocates to the Golgi apparatus, where undergoes a series of 
irreversible proteolytic processes, including the cleavage of its LD by serine protease 
site-1 protease (S1P) and metalloprotease site 2-protease (S2P) (Shen and Prywes, 
2004). Cleavage allows the ATF6’s transcriptional domain, at 50kDa, to translocate to 
the nucleus where it regulates genes that contains ATF-cAMP response elements 
(Wang et al., 2000). This allows the upregulation of UPR-associated genes including 
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BiP, protein disulphide isomerase, and ERAD-associated ER degradation-enhancing 
alpha-mannosidase-like protein 1 (EDEM1) (Chakrabarti et al., 2011). UPR pathways 
also appear to be interlinked, as EDEM1 is also induced through the IRE1 pathway 
and ATF6 induces the expression of XBP1 (Yoshida et al., 2001). XBP1 signalling 
appears to be a negative regulator of ATF6 signalling, as findings from Yoshida et al., 
(2009) identified that an increase in XBP1u leads to a reduction in ATF6 signalling. 
XBP1u binds to ATF6α, leading to proteasomal degradation of the protein (Yoshida et 
al., 2009). ATF6 also regulates cell fate by inducing the expression of regulator of 
calcineurin 1 (RCAN1). RCAN1 can inhibit calcineurin 1 expression, which prevents 
the sequestering of Bcl-2 and therefore prevents pro-apoptotic signalling (Chakrabarti 
et al., 2011). Therefore, it appears that all UPR signalling pathways have a direct 













Figure 6 - UPR signalling during ER stress.  
Author’s representation of the three UPR arms which regulate proteostasis during ER stress. 
Activated IRE1 allows the splicing of XBP1, which increases protein folding and overall quality 
control of the proteins produced. XBP1 also increases the capacity of the ER through lipid 
biogenesis to cope with the increased stress. The PERK arm allows the phosphorylation of eif2α, 
which inhibits further protein production and allows the activation of ATF4. Increased ATF4 can 
determine cell fate through the manipulation of autophagy and apoptotic signalling. ATF4 also 
regulates the oxidative stress response during the presence of accumulating ROS. ATF6 is 
activated within the Golgi apparatus and subsequently allows the increased expression of UPR 
genes BiP, XBP1 and CHOP. 
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1.7. ER Stress and UPR signalling in IBD 
As discussed previously, Paneth cell dysfunction has been linked to IBD, with 
susceptibility genes such as NOD2 and ATG16L1 being found to regulate α-defensin 
production and intracellular granule formation within Paneth cells respectively 
(Okamoto and Watanabe, 2016).  Around 30% of newly synthesised proteins are 
misfolded during their formation within normal conditions (Liu et al., 2016). Therefore, 
highly secretory cells, such as Paneth cells, are more susceptible to elevated ER 
stress due to the increased likelihood of the accumulation of misfolded proteins within 
the ER, which can be induced through inflammatory mediators and microorganisms 
within the intestine (Kaser et al., 2008a).  
The UPR is critical in maintaining cell homeostasis during ER stress and the ability for 
the UPR to activate autophagy to degrade misfolded proteins is crucial (Figure 7) 
(Ogata et al., 2006). Autophagy has been shown to be induced by the UPR through 
the induction of the PERK-eIF2α pathway. The PERK-eIF2α pathway transcribes 
ATF4 and CHOP, which can subsequently activate autophagy genes p62, Atg16L1 
and Map1lc3B that all contain similar amino acid response elements (B’Chir et al., 
2013). Adolph et al. (2013) concurred with the previous statement indicating variants 
within XBP1 induced autophagy to compensate for the lack of UPR activation. When 
Xbp1 null mice were treated with the mTORC1 inhibitor, rapamycin, there were a 
significant decrease in enteritis, NF-κB activation and apoptosis of cells. This effect 
was not observed within ATG16L1/Xbp1 and Atg7/Xbp1 null mice, indicating the 
importance of functional autophagy within inflammation (Adolph et al., 2013). It was 
also discovered silencing of ATG7 and XBP1 gave rise to discontinuous submucosal 
inflammation that was similar to what is seen in CD; indicating that insufficient 
autophagy activity is key to the inflammatory phenotype (Adolph et al., 2013). Without 
sufficient autophagy activity, sustained MAPK8 activation would occur leading to the 
dissociation of Bax from Bcl-2 and caspase-3 activation. This would lead to apoptosis 
of the cells and impair IEC barrier integrity (Wei et al., 2008).  
The ER stress within Paneth cells caused by the T300A variant within ATG16L1 has 
also been correlated with bacterial persistence (Deuring et al., 2014). This correlates 
with studies that have shown that NOD2, which regulates bacterial persistence, utilises 
autophagy to remove pathogens (Travassos et al., 2010). NOD2 has also been found 
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to induce IRE1α dependent splicing of Xbp1, a common UPR transcription factor that 
has been known to induce autophagy through BECLIN-1 transcription (Margariti et al., 
2013). This illustrates that NOD2, UPR and the autophagy pathway are interlinked and 
the inability for these pathways to induce autophagy is one of the key reasons for 






Figure 7 - The Function of Paneth cells and autophagy in Intestinal epithelium 
physiology.  
Misfolded proteins accumulate within Paneth cells (orange) due to the high production of host 




1.8. Clinical Relevance of Thiopurines 
Thiopurines, which include azathioprine (AZA), 6-mercaptopurine (6-MP) and 6-
thioguanine (6-TG), have been commonly used in IBD treatment as an 
immunosuppressant (Kapur and Hanauer, 2019). As shown on (Figure 8), AZA is 
converted to 6-MP through a conjugation reaction using glutathione (GSH) (Eklund et 
al., 2006). The drug then undergoes a series of metabolic reactions to form two main 
metabolic groups that are the phosphorylated thioguanine nucleotides (6-TGNs), and 
methylated thioinosine phosphates (Atreya and Neurath, 2008). The nucleotides can 
then intercalate into genomic DNA that can lead to nucleotide mispairing and cell cycle 
arrest; ultimately causing immunosuppression and cytotoxicity (Stocco et al., 2015). 
Thiopurines are given to IBD patients to maintain remission, as meta-analysis data 
has shown that 73% of CD patients treated with AZA maintain remission over an 18-
month period compared to 62% in a control group (Chande et al., 2015)  
Discussion has been raised to the effectiveness of thiopurines as a monotherapy, as 
the onset of its therapeutic action ranges from 12-17 weeks from the beginning of 
treatment (Goel et al., 2015). For example, infliximab and AZA treatment together was 
found to be more effective in inducing and maintaining remission in patients compared 
to infliximab or AZA alone (Colombel et al., 2010). In addition, an increase of 24.1% in 
steroid free remission was observed in patients treated with combination therapy 
compared to monotherapy alone (D’Haens, 2008). The anti-metabolite effect of 
thiopurine treatment is only effective in relatively high doses, such as with oncological 
treatment, therefore the mechanism of action is not fully elucidated (Seinen et al., 
2016). This is reinstated by the fact only 10-45% of IBD patients respond effectively to 
the treatment (Chaabane and Appell, 2016). In addition, 30% of IBD patients are 
forced to discontinue treatment due to adverse effects associated with thiopurines, 
including hepatoxicity and myelotoxicity (Haglund et al., 2013). Thiopurines could be 
exerting their effects in part through the modulation of the autophagy pathway. It was 
identified during thiopurine-induced hepatotoxicity, autophagy was increased to 
protect hepatocytes from the deleterious effects of thiopurines (Guijarro et al., 2012). 
This was supported by Chaabane & Appell et al. (2016) who illustrated autophagy was 
a protective mechanism preventing apoptosis through the removal of damaged 





Figure 8 - The Metabolism of Thiopurines.  
AZA is metabolised into 6-MP which is then subsequently metabolised further in 6-TGN. 6-TGN can 
either intercalate within DNA or inhibit RAC1 to cause immunosuppression. 6-TG bypasses the 
metabolic steps to be converted to 6-TGN by hypoxanthine-guanine phosphoribosyl transferase 
(HPRT). The arrows highlighted in red are hypothesised ways in which autophagy could be induced 
during thiopurine metabolism. Abbreviations: Thiopurine methyltransferase (TPMT), 6-methyl 
mercaptopurine (6-MMP), 6-methyl mercaptopurine ribnucleotide (6-MMPR), inosine monophosphate 
dehydrogenase (IMPDH), 6-thioguanine nucleotide (6-TGN), xanthine oxidase (XO), 6-
methylthioinosine monophosphate (6-MeTIMP), guanosine monophosphate synthetase (GMPS), 











1.8.1. Potential Mechanism of Action of Thiopurines 
As highlighted in red in Figure 8, many pathways could be involved in the stimulation 
of autophagy during thiopurine treatment. One of the key findings by Hooper et al., 
(2019) is that AZA-induced autophagy was attenuated in the presence of a PERK 
inhibitor, indicating PERK activation is critical in autophagy stimulation observed 
during thiopurine treatment. The mitochondria are severely affected during thiopurine 
treatment, with mitochondrial permeabilisation and increased ROS production being 
commonly observed (Chaabane and Appell, 2016). PERK has been previously found 
to be an oxidative stress sensor during extracellular matrix detachment and induces 
autophagy to relieve ROS accumulation (Avivar-Valderas et al., 2011). PERK has also 
been found to regulate communication between the mitochondria and ER through 
MAM’s, by working as a tether and conveying pro-apoptotic signals during ROS-
mediated ER stress (Verfaillie et al., 2012). In addition, PERK regulates mitochondrial 
morphology during ER-stress and protects the mitochondria by inducing the 
expression of parkin through ATF4, a known inducer of mitophagy (degradation of the 
mitochondria by autophagy) (Bouman et al., 2011; Lebeau et al., 2018). Therefore, 
there is the possibility that PERK plays a cytoprotective role within the mitochondria 
during thiopurine treatment; and this subsequent activation relieves ER stress within 
the cell. 
One of the key unpublished findings by Hooper et al., (2019) was that the metabolite 
6-MP was not as strong an inducer of autophagy as AZA, suggesting that the 
metabolism of AZA may be a key factor involved in autophagy stimulation. Two critical 
steps have been found to take place during the conversion of AZA to 6-MP. The first 
is the displacement of the imidazole ring which is present on the structure of AZA. This 
is due to the conversion of AZA to 6-MP by biogenic thiols, such as GSH, which allows 
the detachment of methyl-4-nitro-5-imidazole (Warner et al., 2016). The therapeutic 
action of imidazole derivatives during AZA metabolism has been briefly explored by 
Crawford et al., (1996), which hypothesised that imidazole heteroarylation of thiol 
groups enriched on lymphocyte membranes could be responsible for its 
immunosuppressive effects. Particular imidazole conjugates have also illustrated PI3K 
inhibitory activity (Mohan et al., 2016). If the imidazole derivatives that are released 
during AZA metabolism also exhibited the same inhibitory effect towards PI3K, this 
could explain how AZA could be inducing autophagy activity.  
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The second critical step during AZA metabolism is the consumption of intracellular 
GSH within the cell (Eklund et al., 2006). There are a variety of different mechanisms 
in which GSH consumption could potentially induce autophagy activity. Examples of 
this are the production of ROS during GSH depletion, potentially regulating ATG 
proteins such as thiol containing ATG4. Mitophagy has also been shown to be 
regulated by intracellular GSH within yeast cells (Deffieu et al., 2009). In addition, 
deletion of the glutathione-S-transferase subtype, GSTM1, resulted in a reduction in 
the response to AZA within IBD patients (Stocco et al., 2014a)  
Hooper et al., (2019) also observed mTORC1 inhibition during AZA treatment. 
However, the inhibition of PERK did not affect mTORC1 activity, indicating that 
mTORC1 inhibition may be upstream or parallel to PERK during thiopurine treatment. 
The 6-TGN metabolite, 6-thioguanine-triphosphate, has been found to induce 
apoptosis within CD4+ cells through the inhibition of Rac1 (Tiede et al., 2003). 
Interestingly, Rac1 has been shown to mediate the localisation of mTORC1 to the 
cellular membrane within serum stimulated HeLa cells (Saci et al., 2011). Therefore, 
AZA could induce autophagy through the inhibition of mTORC1 by the suppression of 
Rac1. This concept is supported from a study that identified that the ATG16L1 risk 
allele resulted in Rac1 hyperactivation and these individuals responded more 
effectively to thiopurine treatment (Wildenberg et al., 2017). mTORC1 and PERK 
signalling have been linked through an array of different mechanisms that differ 
depending on stress stimuli and proliferation rate of cells (Gandin et al., 2016). 
Therefore, it is critical to characterise the activity of these pathways during thiopurine 
treatment within cell lines that are relevant to IBD, such as IEC’s and macrophages. 
mTORC1 has also been linked to other UPR signalling pathways, with mTORC1 
inhibition leading to prolonged IRE1 clustering and increased splicing activity 
(Sanchez-Alvarez et al., 2017). It would therefore also be of interest to determine 
whether other UPR signalling pathways are activated, and if so, how they interact with 






1.9. Research aims 
Autophagy is dysfunctional in IBD patients, and pharmaceutical induction of autophagy 
may be therapeutically beneficial for the treatment of IBD (Mutalib et al., 2014). 
Previous studies have shown that AZA modulates autophagy activity independent of 
apoptosis through mechanisms involving the UPR kinase, PERK, and mTORC1. 
However, thiopurine metabolites, 6-MP and 6-TG, have not been investigated in this 
context.  
The aims of this study are to: 
• Characterise the effects of thiopurines on autophagy pathway activity. 
• Investigate the effects of thiopurines on apoptosis. 
• Characterise the effects of thiopurines on ER-stress/UPR signalling. 



















Chapter 2. Materials and Methods 
2.1. Cell Culture 
Human embryonic kidney 293 cells (HEK293) stably expressing GFP-LC3 (a gift from 
Dr Craig Stevens) were grown in Dulbecco’s modified eagle’s media (DMEM) (Gibco, 
Thermofisher Scientific, Paisley, UK) supplemented with 10% FBS (Gibco) and 1% 
penicillin/streptomycin (Gibco). Cells were incubated at 37°C in 5% CO2 and were 
passaged every 2-3 days. THP-1 cells were grown in Roswell park memorial institute 
(RPMI) 1640 (Sigma-Aldrich, Irvine, UK) supplemented with 10% FBS, 1% L-
glutamine (Gibco) and 1% penicillin/streptomycin.  THP-1 cells were incubated at 37°C 
in 5% CO2 and were passaged every 2-3 days. THP-1 monocytes were differentiated 
into macrophages by growth in RPMI supplemented with 20ng/ml of phorbol 12-
myristate 13-acetate (PMA) (Tocris, Bristol, UK) for 48 hours, then rested for 24 hours 
in fresh RPMI prior to experiments.   
 
2.2. Transfection and plasmids 
Adherent THP-1 derived macrophages were detached from tissue culture plates using 
accutase 1 (PromoCell, Heidelberg, Germany) collected into 15ml falcon tubes 
(Falcon, Corning International, US) and centrifuged at 250xg for 10 minutes 
(Pendragon, Scientific Ltd). Supernatant was aspirated and cell pellets were 
resuspended in 100µl nucleofector solution (Lonza, Manchester, UK). 0.5µg of GFP-
RFP-LC3 plasmid (A gift from Dr Craig Stevens, Edinbugh Napier University UK) was 
then added to the cell suspension, gently mixed and transferred to a nucleofector 
cuvette (Lonza). Cells were electroporated using the Y-001 programme according to 
the manufacturer’s instructions with the Nucelofector 2b device (Lonza). Fresh RPMI 
(500µl) was added to the transfected cells and the cell suspension combined with a 
further 1ml of RPMI in a 6-well plate. Cells were incubated for 24hrs prior to analysis 






2.3. Cell treatments 
Cells were washed using 0.9% isotonic NaCl prior to treatment. Pharmacological 
agents were reconstituted and stored in Dimethyl Sulfoxide (DMSO, Sigma). 
Pharmacological agents were diluted to a working concentration in culture media and 
cells were treated for an appropriate incubation time. An equivalent amount of DMSO 
was used as a vehicle control. Incubation times and concentrations used for the 
optimisation of techniques was derived from previous findings by Hooper et al. (2019). 
All pharmacological agents used are detailed in (Table 2). 
Table 2 - Pharmacological Agents 




AZA 100mM/ml 20-120μM 0-24 Tocris 
6-MP 90mM/ml 20-120μM 0-24 Tocris 
6-TG 10mg/ml 20-120μM 0-24 Tocris 
IL-13 100μg/ml 20ng/ml 24 Sigma 
IL-14 100μg/ml 20ng/ml 24 Invivogen 
LPS 5mg/ml 100ng/ml 24 Invivogen 
IFN-γ 1mg/ml 20ng/ml 24 Peprotech 
PMA 100μg/ml 5-20ng/ml 48 Tocris 
Tunicamycin 5mg/ml 5µg/ml 8 Sigma 
Brefeldin A 10mg/ml 1µg/ml 8 Cayman 
Bafilomycin 1mg/ml 160nm 8 Santa Cruz 
Biotechnology 
 
2.4. Western immunoblotting 
Cells were washed with phosphate buffered saline (pH 7.4) (PBS) (Sigma), detached 
from tissue culture plates using 0.5% Trypsin-EDTA (Gibco), transferred into 
Eppendorf tubes, and centrifuged at 3000 RPM for 5 minutes. Supernatant was 
removed and cell pellets frozen at -80°C or lysed on ice for 30 minutes in buffer 
containing 1 x protease and phosphatase inhibitor cocktail (50mM Tris pH8, 150mM 
NaCl, 1mM EDTA and 1% NP-40). Lysates were then centrifuged at 12,000 RPM at 
4°C for 5 minutes and supernatants stored at -20°C.  
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Protein concentration of lysate was measured using Bradford assay by adding 5μl of 
sample or BSA standard to 195μl of Bradford Reagent (Sigma-Aldrich) and measuring 
absorbance at 595nm using an MRX II absorbance reader (LT-5000 MS ELISA 
Reader).  
25μg of protein lysate and 5μl of PageRuler Plus prestained protein ladder (Thermo 
Scientific) were resolved by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at 180V for 50 minutes using a stacking gel (pH 6.8) and 
an 8-12% acrylamide resolving gel (pH 8.8). SDS-PAGE gels were manufactured 
using a Biorad casting frame. Resolving gel (30% Acrylamide, 1.5M Tris pH 8.85, 10% 
SDS, 10% Ammonium Peroxidosulphate, TEMED) was initially added to the casting 
frame with an additional layer of isopropanol to prevent the formation of air bubbles. 
Isopropanol was removed from the casting frame and an additional layer of stacking 
gel (30% Acrylamide, 1M Tris pH 6.68, 10% SDS, 10% Ammonium Peroxidosulphate, 
TEMED) was poured into the casting gel containing solidified resolving gel. A comb 
was placed into the stacking gel while the gel solidified. Electrophoresis was 
performed using a Mini-PROTEAN Tetra Vertical Electrophoresis cell (Bio-Rad, UK). 
Proteins were electrotransferred onto nitrocellulose membrane in Tris-Glycine buffer 
for 60 minutes at 100V, using a Mini-PROTEAN Cell. The efficiency of protein transfer 
was analysed by ponceau staining (Sigma). Membranes were blocked either with 10% 
non-fat skimmed milk (Marvel) or 5% BSA in PBS + 0.1% Tween (PBS/T) for 1 hour. 
Primary antibodies, diluted to 1:1000-1:2000 in PBS/T supplemented with either 10% 
Marvel or 5% BSA (VWR Chemical, Pennsylvania, US), were incubated with 
membrane at 4°C, overnight, and subsequently washed 3x with PBS/T for 5 minutes 
(Table 3). Membranes were incubated with a secondary antibody diluted to either 
1:2000-1:4000 in PBS/T supplemented with 10% Marvel or 5% BSA for 1 hour at RT, 
washed 3x in PBS/T for 5 minutes, and proteins  visualised using an Odyssey imaging 






Table 3 - Antibodies 
Target Antigen Antibody Type Dilution Diluent Manufacturer 
LC3 Rabbit Polyclonal 1:1000 1% FBS/PBS MBL 
Anti-Rabbit HRP-conjugated 
Goat (680LT) 





1:40 PBS Biolegend 
CD80 Mouse 
Monoclonal 
1:40 PBS Biolegend 
CD68 Mouse 
Monoclonal 
1:40 PBS Biolegend 
P-Eif2α Rabbit 
Monoclonal 












1:2000 5% BSA in 
PBS/T 
Odyssey 


























1:2000 10% Marvel 
in PBS/T 
Dako 
2.5. Fixed cell imaging  
Cells were seeded in a 6-well plate (Costar, Corning international) containing a sterile 
22mm coverslip (VWR international) and grown to 70-80% confluence. After 
appropriate treatment with pharmacological agents, cells were washed with PBS 
(Sigma) and fixed to the coverslip by incubating with PBS-4% Paraformaldehyde 
(PFA) (Sigma, Aldrich) for 15 minutes. 
For cell lines stably expressing GFP-LC3, cells were washed in PBS, mounted directly 
onto slides, and nuclei stained using Vectashield mounting media with DAPI (Vector, 
Vector Laboratories). Coverslips were sealed around the edges to prevent dehydration 
using nail varnish and images captured using an LSM 880 confocal microscope with 
ZenBlue software (Carl Zeiss). 
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For staining with antibodies, cells were permeabilised by incubation with 0.1% Triton 
X (Fisher, Biosciences) for 10 minutes, washed with PBS and blocked for 30 minutes 
with 10% FBS at RT. Cells were again washed in PBS and incubated with primary 
antibody overnight at 4°C (Table 3). Cells were subsequently washed in PBS and 
incubated with the secondary IgG antibody in the dark, at RT, for 1 hour. Coverslips 
were processed and images of cells captured using an LSM 880 confocal microscope 
as described above.  
2.6. Live cell imaging  
HEK293 cells stably expressing GFP-LC3 were grown in glass bottom plates (IBIDI, 
Gräfelfing, Germany) until the cells reached 70-80% confluence, then treated with 
pharmacological agents as appropriate and images captured on an LSM 880 confocal 
microscope (Zeiss) every 20 minutes for 24 hours. Cell growth conditions were 
maintained at 37°C and 5% CO2 for the duration of the experiment using a live cell 
imaging chamber (Pecon, Temperature and CO2 controller 2000). 
2.7. Autophagy Assays 
Basal number of autophagosomes in untreated GFP-LC3 engineered HEK293 cells 
was determined to be between 1-4 LC3 puncta. Therefore, HEK293 cells exhibiting >5 
LC3 puncta were regarded as having an induction of autophagy activity. Basal number 
of autophagosomes in untreated THP-1 derived macrophages was determined to be 
between 1-5 LC3 puncta. Therefore, THP-1 derived macrophages exhibiting >6 LC3 
puncta were regarded as having an induction of autophagy activity. For fixed cell 
imaging utilising GFP-LC3 and immunostained LC3, LC3 puncta was quantified from 
10 cells in 3 separate fields of view. For live cell imaging, LC3 puncta from 30 cells 
was quantified from one image every 2 hours. 30 cells were selected based upon 
previous autophagy-based investigations using immunofluorescence imaging, which 
counted between 20-50 cells (Biskou et al., 2019; Rai and Manjithaya, 2015; Runwal 
et al., 2019). Induction of autophagy was calculated as the percentage of cells over 
the set threshold for basal autophagy activity. 
Basal threshold of GFP-RFP-LC3 puncta plus RFP-LC3 puncta in THP-1 
macrophages was determined to be between 1-7 LC3 puncta. Therefore, any GFP-
RFP-LC3 transfected THP-1 macrophage exhibiting >8 LC3 puncta was regarded as 
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exhibiting an induction of autophagy activity. As shown on Figure 9, an increase in 
RFP-LC3 foci is an indicator of an increase in autophagy activity. Therefore RFP-LC3 
foci were quantified in GFP-RFP-LC3 THP-1 derived macrophages to determine an 
increase in autophagy activity. Ten cells transiently expressing GFP-RFP-LC3 were 
quantified from each treatment group. An increase in autophagy activity was 
calculated as the percentage of RFP-LC3 puncta in relation to the number of total 
puncta in each cell. 
 
2.8. Real time quantitative PCR (RT-qPCR) 
After appropriate treatment in 60mm2 dishes, cells were scraped into PBS, and 
centrifuged at 3000 RPM for 5 minutes at 4ºC. Supernatant was removed and cell 
pellets were immediately frozen at -80ºC. Total RNA was extracted from pelleted cells 
using TRIsure (Bioline) according to manufacturing instructions and quantified using 
a NanoDrop 2000 spectrophotometer (Thermo Scientific). RNA integrity and quantity 
Figure 9 - Analysis of autophagy flux.  
GFP-RFP-LC3 is bound to autophagosomes, which results in yellow fluorescence. During 
autophagolysosome formation, GFP fluorescence becomes quenched due to the low pH within the 
lysosome, whereas RFP remains stable, therefore autophagolysosomes fluoresce red. Image created 




were measured using an Agilent 2100 Bioanalyser according to manufacturer’s 
instructions. 2μg of total RNA was reverse transcribed to cDNA using a High-Capacity 
RNA-to-cDNA kit (Applied Biosystems) following manufacturer’s instructions with the 
inclusion of a no reverse transcriptase control for each treatment to control for genomic 
DNA contamination. For qPCR gene expression analysis, each reaction contained 
25ng cDNA template, 150nM forward and reverse primer (Table 4), PrecisionPlus 
qPCR Master Mix (Primer Design) and DEPC-treated water. A no-template control, 
which contain DEPC-treated water instead of cDNA, was used to monitor reagent 
contamination and potential primer-dimer formation. qPCR was performed and 
analysed using a StepOnePlus Real-time PCR system (Applied Biosystems).  
A geNorm kit (Primerdesign) was used to select appropriate reference genes using 
qbase+ software. the 2-ΔΔCT method was used for relative quantification of gene 
expression. 
 
 2.9. Reverse transcription PCR (RT-PCR) 
After appropriate treatment in 60mm2 dishes cDNA was prepared as described above. 
Initially the presence of actin was evaluated to determine if RNA was successfully 
reverse transcribed and to determine the presence of genomic DNA contamination 
within control samples lacking reverse transcriptase. A mastermix was prepared 
containing Mango Mix (BioLine), 100pm/µl Actin forward and reverse primer (see 
Table 4 for primer sequences), 50ng cDNA template and DEPC-treated water. For 
investigation of XBP1, the master mix composed of Mango Mix (BioLine), 100pm/µl 
XBP1 forward and reverse primer, 100ng cDNA and DEPC water. A no-template 
control, which contain DEPC-treated water instead of cDNA, was used to monitor 
reagent contamination.  DNA amplification was performed within a 2720 thermocycler 
(Applied Biosystems) using the following conditions: 95°C for 5 minutes, cycle 35x at 
95°C for 15 seconds, 56°C for 15 seconds,  
72°C for 30 seconds and finally 72°C for 5 minutes. PCR products were resolved by 
electrophoresis on a 1% agarose gel and PCR products visualised using a G:Box 
System (Syngene, Cambridge, UK). 
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Table 4 - Primer Sequence 
 
2.10. Flow Cytometry 
THP-1 derived macrophages (MO) were polarised to either M1 or M2 macrophages 
by incubation for 24 hours with IFN-γ (20ng/ml) and LPS (100ng/ml) or IL-4 (20ng/ml) 
and IL-13 (20ng/ml) respectively. Cell morphology was examined on a Primovert 
brightfield light microscope (Zeiss) and cells harvested by gentle scraping, washed 
with PBS, and incubated with M0 macrophage marker CD68, M2 macrophage marker 
CD163 and M1 macrophage marker CD80 (Table 3) in the dark for 15 minutes. 
Samples were then examined using flow cytometry (FACSCalibur, BD Medical 
Technology). Threshold for all treatment groups was set to 5000 events and stopping 
events to 10,000. 
 
2.11. Annexin/PI Staining  
Cells were stained using the TRITC Annexin V Apoptosis Detection Kit (BD 
Pharmingen). Briefly, cells were detached from the dish using accutase I for 30 
minutes and transferred into a FACS tube. Cells were then washed twice in PBS, 
counted, and resuspended in Annexin V binding buffer  at a concentration of 1x106/ml. 
100ul of cell suspension was transferred into a 5ml FACS tube and 5ul of Brilliant 
Target 
Gene 




XBP1 GGAGTTAAGACAGCGCTTGGGGA TGTTCTGGAGGGGTGACAACTGGG 164 & 138 Eurofins (UK) 
Actin GGGAAATCGTGCGTGACATT CCACAGGACTCCATGCCC 202 Eurofins (UK) 
EDEM1 CGGACGAGTACGAGAAGCG CGTAGCCAAAGACGAACATGC 96 Eurofins (UK) 
PERK GGAAACGAGAGCCGGATTTATT ACTATGTCCATTATGGCAGCTTC 111 Eurofins (UK) 
ATF4 CTCCGGGACAGATTGGATGTT GGCTGCTTATTAGTCTCCTGGAC 165 Eurofins (UK) 
CHOP AGCTGGAAGCCTGGTATGAGG GTGCTTGTGACCTCTGCTGG 178 Eurofins (UK) 
BiP TATGGTGCTGCTGTCCAGGC CTGAGACTTCTTGGTAGGCACC 162 Eurofins (UK) 
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Violet 421 Annexin V  and 5ul of PI solution (BD Pharmingen) were added to the cell 
suspension. Cells were gently vortexed and left to incubate for 15 minutes at RT in the 
dark. 400ul of Annexin V binding buffer was added and analysed on a flow cytometer 
(FACSCelesta, BD Biosciences). Experimental staining controls were utilised to set 
gating parameter and voltage compensation. Voltages and compensation can be 
found in Table 4 and Table 5, respectively.  Threshold for all treatment groups was 
set to 5000 events and stopping events to 10,000. Staining controls included untreated 
cells and cells treated with deionised H20 for 30 minutes. Annexin V fluorescence was 
measured at an excitation wavelength of 405nm and an emission wavelength of 
421nm. PI fluorescence was measured at an excitation wavelength of 488nm and an 
emission wavelength of 610nm. Cell viability was assessed through fluorescence of 
Annexin and PI on the cell surface. Annexin V- PI- cells were grouped as viable cells, 
Annexin V+ PI- cells as early apoptotic cells, and Annexin V+ PI+ as late 
apoptotic/necrotic cells.  






Table 6 – Compensation 
Fluorochrome - % Fluorochrome Spectral 
Overlap 
PerCP-Cy5-5 BV421 76.24 












2.12. Alamar Blue Assay 
Pharmacological agents, prepared in growth media, were supplemented with 10% 
Alamar blue reagent (Invitrogen) prior to incubation with THP-1-derived macrophages 
in a 96-well plate for up to 24 hours. A no-cell control group was also incubated with 
10% Alamar blue. An excitation wavelength of 544nm and emission wavelength of 
590nm was measured in 2-hour cycles using an MRX II absorbance reader (LT-5000 
MS ELISA Reader) and Manta software (Dynex Technologies, Worthing, UK). 
Absorbances were corrected to the no-cell control using MRX II software version 2.1. 
According to manufacturer’s instructions, metabolic activity was calculated using the 
following calculation: 
FI590: Fluorescent intensity at 544nm excitation (590nm emission) 
 
Percentage difference 
between treated                 =  
(FI590 of test agent treated cells − FI590 of media only) x100
(FI590 of untreated cells−FI590 of media only)
 
And control cells 
 
2.13. Statistical Analysis   
Due to time constraints, optimisation-based experiments were performed once, 
therefore statistical analysis was not evaluated. Statistical analysis was performed 
using GraphPad Prism version 7.0 (GraphPad Software, CA, USA) for experiments 
performed in triplicate. Quantitative results were expressed as ± Standard Error Mean 
(SEM). One-way ANOVA was performed with either Tukey’s or Dunnett’s multiple 










Chapter 3. Induction of autophagy by 
thiopurines in HEK293 cells 
3.1. Introduction 
Thiopurines have previously been shown to modulate autophagy activity (Chabbane 
and Appell, 2016; Hooper et al, 2019). Chabbane and Appell, (2016) demonstrated 
that autophagy induction by thiopurines in colorectal cancer cells was a secondary 
cytoprotective effect that prevented apoptosis. In contrast, Hooper et al., (2019) 
demonstrated that AZA induces autophagy independent of apoptosis via mechanisms 
involving modulation of mTORC1 signalling and stimulation of the UPR sensor PERK. 
Additionally, Oancea et al., (2016) showed that 6-TG enhanced autophagy in a TGN-
dependent manner in gut epithelial cell lines, with 6-TG also reducing intracellular 
bacterial replication. Therefore, the initial aim was to assess modulation of autophagy 
in response to thiopurine treatment in HEK293 cells, a human embryonic kidney cell 
line that has been well characterised in terms of autophagy activity and have a very 
high efficiency for transfection (Musiwaro et al., 2013). HEK293 cells engineered to 
stably express the autophagy marker LC3 fused to green fluorescent protein (GFP-
LC3) were available in the laboratory, therefore, initial characterisation of autophagy 
was carried out in HEK293 GFP-LC3 stable cells. HEK293 GFP-LC3 cells have the 
added advantage that live cell imaging of autophagy can be performed, as cell 
permeabilization is not required to visualise GFP-LC3. 
Hypothesis: Thiopurines will induce autophagy in HEK293 GFP-LC3 cells, 
independent of apoptosis. 
Aim 1) To characterise autophagy induction in response to thiopurine treatment. 
Aim 2) To compare live-cell imaging and fixed-cell imaging for the measurement of 
autophagy induction in response to thiopurine treatment. 




3.2.1. Live cell imaging of thiopurine induced autophagy 
Live cell imaging was used to assess the modulation of autophagy over a 12h time 
course in thiopurine-treated HEK293 GFP-LC3 cells. As shown in Figure 10, all 
thiopurines tested induced an accumulation of autophagosomes. The largest increase 
in autophagosomes was observed at the 8h time point, with a 60% increase in cells 
exhibiting >5 LC3 puncta in response to AZA, a 57% increase in cells exhibiting >5 
LC3 puncta in response to 6-MP, and a 37% increase in cells exhibiting >5 LC3 puncta 
in repose to 6-TG relative to control cells (Figure 11). At the 12h time point an 
accumulation of autophagosomes was also observed in control cells, with 26% of cells 
exhibiting >5 LC3 Puncta. Therefore the 8h time point was selected for future 
experiments due to low levels of basal autophagy observed in control cells. AZA 
induced autophagosome accumulation more rapidly than 6-MP and 6-TG, with a 63% 
increase in cells exhibiting >5 LC3 puncta in response to AZA, a 6% increase in cells 
exhibiting >5 LC3 puncta in response to 6-MP, and a 13% increase in cells exhibiting 
>5 LC3 puncta in response to 6-TG relative to the control at the 4h time point (Figure 
11). Taken together these results suggest that all of the thiopurines tested induce 
autophagosome accumulation in HEK293 cells and that AZA induces autophagosome 

































Figure 10 - Induction of autophagy by thiopurines. 
HEK293 GFP-LC3 cells were either treated with DMSO (Control), serum starved (SS), or treated with 120μM of 
AZA, 120μM of 6-MP or 120μM of 6-TG and accumulation of autophagic puncta assessed by live cell imaging 
over 12h. Thirty cells were counted from 3 fields of view and percentage cells with >5 GFP-LC3 puncta quantified 












































Figure 11 - Quantification of autophagy induction by thiopurines.  
Bar graph quantifying the number of HEK293 GFP-LC3 cells exhibiting >5 LC3 puncta in response to 
thiopurine treatment at various time points. Thirty cells from 3 fields of view for each treatment group 












3.2.2. Fixed-cell imaging of thiopurine induced autophagy 
Autophagosome accumulation in response to thiopurine treatment was assessed 
using fixed cell imaging to determine whether the response was comparable to that 
observed using live cell imaging. The 8h time point was selected as it was the timepoint 
when levels of basal autophagy were low and the largest accumulation of 
autophagosomes was observed in response to thiopurine treatment using live cell 
imaging. As shown in Figure 12A an increase in autophagosome accumulation was 
observed in response to thiopurine treatment, with a 30% increase in cells exhibiting 
>5 LC3 puncta in AZA treated cells relative to untreated control cells (Figure 12B). 
Similarly, 6-TG treatment resulted in a 33% increase in cells exhibiting >5 LC3 puncta 
relative to the untreated control (Figure 12B). In contrast, we did not observe an 
increase in LC3 puncta in response to 6-MP treatment in fixed cells, which is not in 
agreement with our findings using live-cell imaging. These results indicate that fixed 
cell imaging is not as sensitive as live cell imaging in the context of LC3 quantification, 
with autophagosome accumulation not observed in response to  6-MP treatment after 
8h, while AZA produced only a 30% increase in cells exhibiting >5 LC3 autophagic 
puncta after 8h treatment compared to 60% observed with live-cell imaging. However, 


































Figure 12 - Induction of autophagy by thiopurines at 8h time point using fixed-
cell imaging. 
(A) - HEK293 GFP-LC3 cells were treated with DMSO (Control) (i), serum starved (ii), or treated with 
120μM AZA (iii), 120μM 6-MP (iv) or 120μM 6-TG (v) for 8h. Cells were fixed and mounted onto slides 
and thirty cells were counted from 3 fields of view and percentage cells with >5 GFP-LC3 puncta 
quantified (+/- SEM). Images captured at 630x magnification using a Carl Zeiss LSM880 confocal 
microscope. n=1. 
(B) - Bar graph quantifying HEK293 cells exhibiting >5 LC3 puncta in response to 8h thiopurine 




3.2.3. Fixed-cell imaging of sustained thiopurine induced autophagy 
Autophagosome accumulation was assessed at a later time-point using fixed cell 
imaging to determine if the autophagy activity observed at the 8h time-point was 
sustained. HEK293 GFP-LC3 cells were treated with thiopurines for 24h and LC3 
puncta quantified. As shown in Figure 13A, an increase in autophagosome 
accumulation was observed in response to thiopurine treatment, with a 49% of cells 
exhibiting >5 LC3 puncta in AZA treated cells relative to untreated control cells (Figure 
13B). 6-MP and 6-TG treatment caused a 33% and 39% increase in cells exhibiting 
>5 LC3 puncta respectively compared to the untreated control cells (Figure 13B). 
These fixed cell imaging results are comparable with results obtained from live cell 
imaging and demonstrate that autophagosome accumulation is sustained for at least 

























Figure 13 - Induction of autophagy by thiopurines at 24h time point. 
(A) - HEK293 GFP-LC3 cells were either treated DMSO (Control) (i), serum starved (SS) (ii), or treated 
with 120μM AZA (iii), 120μM 6-MP (iv) or 120μM 6-TG (v) for 24h. Cells were fixed and mounted onto 
slides and thirty cells were counted from 3 fields of view and percentage cells with >5 GFP-LC3 puncta 
quantified. Images were captured at 630x magnification using a Carl Zeiss LSM880 confocal 
microscope. n=1. 
(B) - Bar graph quantifying HEK293 cells exhibiting >5 LC3 puncta in response to 24h thiopurine 




3.2.4. Effect of thiopurines on metabolic activity and cell morphology 
Using live cell imaging, changes in cell morphology were observed in 6-TG treated 
HEK293 GFP-LC3 cells. Morphological changes are often associated with 
physiological stress; therefore, the metabolic activity of cells was assessed using 
Alamar Blue assay to determine whether thiopurines were cytotoxic. HEK293 cells 
were treated with thiopurines at 120μM and brightfield images were captured at 0, 2, 
4, 6, 8 and 24h time points. As shown in Figure 14A, AZA and 6-MP did not alter the 
metabolic activity of cells throughout the 24h incubation period. In contrast, 6-TG 
initially reduced the metabolic activity of cells to 65% at the 2h time point relative to 
control, which gradually recovered over time until 105% relative to the control was 
observed at the 24h time point. Light microscopy images shown in Figure 14B were 
consistent with these findings, with no observable differences in cell morphology 
observed in AZA, 6-MP and control treated cells. In contrast, 6-TG-treated cells 
exhibited a more compact morphology at the 2h time point (Figure 14B panel XIV). A 
reduction in growth was also observed, with 6-TG-treated cells reaching a confluency 
of 50% compared to the control, with the control cells reaching almost 100% 
confluency after 24h (Figure 14B, compare panels XXV and XIX). These results 

































Figure 14 - Effect of thiopurines on metabolic activity and cell growth 
(A) - HEK293 cells were either treated with DMSO (Control), 120μM AZA, 120μM 6-MP, or 120μM 6-
TG for up to 24h and metabolic activity measured using Alamar Blue. n=1.  
(B) – Effect of thiopurines on cell proliferation was assessed using light microscopy. HEK293 cells were 
either left untreated, or treated with 120μM AZA, 120μM 6-MP, or 120μM 6-TG. Images were captured 





Initially, a time course of thiopurine treatment was performed and induction of 
autophagy assessed using live cell imaging. AZA induced an accumulation of 
autophagosomes after 4h compared to 6-MP and 6-TG, which did not begin to induce 
autophagosome accumulation until the 6h time point. The largest increase in 
autophagosome accumulation was observed at 8h, therefore, the 8h time point was 
selected and used to compare live cell imaging results with fixed cell imaging. Although 
fixed cell imaging did not appear to be as sensitive method of measuring 
autophagosome accumulation when compared to live-cell imaging, a difference 
between the control, AZA and 6-TG treated cells was observed, with AZA and 6-TG 
clearly increasing autophagosome accumulation at the 8h time point. In contrast, 6-
MP did not appear to increase autophagosome accumulation at 8h when fixed cell 
imaging was used. After a 24h incubation all thiopurine-treated cells exhibited an 
accumulation of autophagosomes using fixed-cell imaging, indicating that all 
thiopurines induce a sustained autophagy response.   
Experiments performed within this chapter were performed once, to allow for 
optimisation of techniques prior to proceeding experiments with THP-1 macrophages. 
This prevented statistical analysis of data, which in turns limited the ability to reach 
definitive conclusions. In addition, the accumulation of autophagosomes observed 
using live cell and fixed cell imaging does not determine whether thiopurine treatment 
causes autophagy activation, as autophagosome accumulation can also result from 
inhibition of autophagy due to blockage of autophagosome-lysosome fusion. 
Therefore, additional experiments are required to determine whether thiopurines are 
activating autophagy.  
Morphological changes were observed in 6-TG treated cells during live cell imaging, 
we therefore further investigated these morphological changes using light microscopy. 
The effects on cell morphology observed using live cell imaging were reproduced 
using light microscopy, with 6-TG treated cells exhibiting altered morphology and 
reduced growth compared to the control, AZA and 6-MP treated cells. These 
observations were further investigated using an Alamar blue assay, which showed  
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cells have reduced metabolic activity in response to 6-TG treatment at early time 
points when compared to the control, AZA and 6-MP.   
Taken altogether, these results suggest that AZA and 6-TG can induce 
autophagosome accumulation at the 8h timepoint, which was not observed in 6-MP 
treatment. However, all thiopurines induced autophagosome accumulation at the 24h 
timepoint. In addition, 6-TG-treated cells shown a reduction in both growth and 
metabolic activity, which was not observed in AZA or 6-MP treatment. Additional 
experiments are required to determine whether autophagy is being activated in 























Chapter 4. Characterisation of autophagy 
induction by thiopurines in macrophages  
4.1. Introduction 
Macrophage function is extremely important in CD pathogenesis (Mahida, 2000). Of 
note, it has recently been reported that AIEC were able to replicate within MDM from 
CD patients but not within MDM from UC patients or healthy subjects, suggesting that 
CD MDM are unable to control intracellular bacteria; which leads to a sustained 
inflammatory response (Vazeille et al., 2015). Several genetic variants have been 
identified as CD susceptibility factors which could directly affect the function of 
macrophages (Cho and Brant, 2011), with in vitro studies demonstrating the impact of 
CD-associated single nucleotide polymorphisms related to autophagy on AIEC 
survival (Lapaquette et al., 2012) 
Monocytic THP-1 cells are the most commonly used cell line for in vitro studies 
investigating human macrophage function (Lund et al., 2016). They are very well 
characterised and can be differentiated into a variety of macrophage subsets (Starr et 
al., 2018), and therefore provide a good model in which to conduct the studies detailed 
herein. 
 
Hypothesis: Thiopurines induce autophagy in THP-1 derived macrophages. 
Aim 1: Differentiate THP-1 monocytes into macrophages. 
Aim 2: Characterise autophagy induction by thiopurines in macrophages 








4.2.1. Differentiation of THP-1 derived macrophages 
THP-1 monocytes can be differentiated to exhibit a macrophage like phenotype that 
closely resembles macrophages in vivo. Due to variation in published methodologies 
used to differentiate THP-1 cells, initial optimisation of PMA concentration was 
required. Concentrations of PMA over 100ng/ml have been shown to sensitise THP-1 
cells to various stimuli (Lund et al., 2016), therefore, PMA concentrations ranging from 
5ng/ml to 20ng/ml were assessed. The most commonly used read-out for 
differentiation of THP-1 cells to macrophages is adherence of cells accompanied by 
morphological changes. When undifferentiated, cells are in suspension and appear 
rounded, however they become adherent to the culture plate or flask, and exhibit 
morphological flattening when differentiation occurs (Lund et al., 2016). Therefore, the 
percentage of adherence was used to determine the effectiveness of each 
concentration of PMA for differentiation of THP-1 cells. As shown in Figure 15A, 
treatment with PMA at 20ng/ml induced the highest proportion of cell adherence, with 
cells exhibiting 98% adherence. Figure 15B, panel ii shows the morphological 
changes that can be observed with PMA differentiation at 20ng/ml, with cells exhibiting 
a flatter, more protruded phenotype compared to control (Figure 15B, panel i). Both 
the adherence, and the morphological changes observed in PMA-treated samples 
























Figure 15 - PMA treatment induces THP-1 morphological changes and cellular 
adherence. 
(A) – THP-1 cells were incubated with different concentrations of PMA (5-20ng/ml) for 48 hours, and 
then rested in fresh media for 24 hours. The number of non-adherent cells was subtracted from the 
seeding density to determine the % of adherence during each treatment. n=1.  
(B) - THP-1 cells were treated with either, 5, 10, 15 or 20ng/ml of PMA for 48 hours and then rested in 
fresh media for 24 hours. Adherence was monitored through light microscopy. Images illustrate THP-1 
cells before treatment and 48 hours with 20ng/ml PMA treatment. Images were captured at 100x 




4.2.2. Characterisation of THP-1 derived macrophages 
The morphological changes observed in THP-1 derived macrophages following PMA 
treatment required further validation using well-known macrophage surface markers 
to confirm if differentiation had occurred. Therefore, flow cytometric analysis was 
performed using common macrophage markers CD68, CD163 and CD80. Cells were 
also compared to M1 and M2-macrophage control cells to determine whether 
polarisation of cells occurs during PMA treatment. As shown in Figure 16, a clear 
difference in morphology was observed between PMA-treated cells (Figure 16, panel 
iv) and M1 (Figure 16, panel v) and M2 (Figure 16, panel vi) macrophages. M1 
macrophages appear to show a more flattened morphology and M2 macrophages 
appear to exhibit more protrusions. As PMA-only treatment did not induce either of 
these morphological changes consistently, this indicates that PMA treatment did not 
polarise THP-1 cells towards either one of these particular subsets. 
As shown in Figure 17, flow cytometric analysis revealed differences in marker 
expression between macrophage subsets. Undifferentiated THP-1 cells exhibited low 
expression for all markers examined. PMA-only treated cells exhibited a small 
increase in CD68 and CD80 expression compared to undifferentiated cells with an 
18.33% and 20.79% increase in CD68 and CD80 expression, respectively, relative to 
the control. PMA-only treated cells exhibited a considerable increase in CD163 
expression of 61.05% relative to untreated cells. PMA-only treated cells also exhibited 
a distinct difference in marker expression compared to the M1 and M2 macrophage 
controls, with PMA-only treated cells exhibiting low CD68 expression of 24.7% 
compared to 48.3% and 63.9% compared to the M1 and M2 macrophage controls 
respectively. PMA-only treated cells also did not exhibit similar CD80 expression to 
the M1 and M2 macrophages, with PMA-only treated cells showing a 26.2% 
expression of CD80 compared to the M1 and M2 macrophages that exhibited a 87.9% 
and 92.2% CD80 expression respectively, indicating that differentiation of THP-1 cells 










Figure 16 - Morphological changes during polarisation of THP-1 cells.  
THP-1 cells were  treated with PMA only (20ng/ml) for 48 hours (panels i + iv), treated with PMA for 
24h and then supplemented with LPS (100ng/ml) and IFN-γ (20ng/ml) in PMA containing media for a 
further 24h (panels ii + v),  or treated with PMA for 24h and subsequently treated with IL-4 (20ng/ml) 
and IL-13 (20ng/ml) in PMA containing media for a further 24h (panels iii + vi). Images were captured 





























Figure 17 - Macrophage marker expression in polarised THP-1 cells.  
THP-1 cells were seeded and either treated with PMA only (20ng/ml) for 48h, treated with PMA for 24h 
and subsequently treated with LPS (100ng/ml) and IFN-γ (20ng/ml) in PMA containing media for a 
further 24h (M1) or treated with PMA for 24h and subsequently treated with IL-4 (20ng/ml) and IL-13 
(20ng/ml) in PMA containing media for a further 24h. Cells were then harvested and incubated with 
CD163-PE, CD68-FITC and CD80-APC antibody. Marker expression was analysed through flow 
cytometric analysis. n=1. 
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4.2.3. Time-Course of autophagy induction by thiopurines in THP-1 derived 
macrophages  
A time course, utilising fixed cell imaging, was performed to assess any differences in 
autophagy activity mediated by thiopurines over a range of different time points, and 
to select an appropriate time point for subsequent experiments. Time points ranging 
between 2h to 8h were tested, as the 8h time point exhibited optimal autophagosome 
accumulation in thiopurine-treated HEK293 cells. As shown in Figure 18 & 19A, 
autophagosome accumulation was observed in response to thiopurine treatment in a 
time dependent manner. The 8h time point showed the highest accumulation of 
autophagosomes, with 6-MP treatment inducing the highest accumulation, with a 49% 
increase in cells exhibiting >6 LC3 puncta relative to the control. Similarly, AZA and 6-
TG caused an increase in autophagosome accumulation, with a 31% increase in cells 
exhibiting >6 LC3 puncta and a 30% increase in cells exhibiting >6 LC3 puncta relative 
to control (Figure 19B). This data demonstrates that the 8h time point is the optimum 
time point to observe autophagosome accumulation in response to thiopurines in THP-





































Figure 18 – Time course of autophagy induction in thiopurine treated THP-1 
derived macrophages.  
THP-1 derived macrophages were either treated with DMSO (Control), serum starved (SS), treated 
with 120μM AZA, 120μM of 6-MP, or 120μM of 6-TG. THP-1 derived macrophages were left to incubate 
for either 0, 2, 4, 6 or 8h with the pharmaceutical agent. Samples were fixed, immunostained using an 
anti-LC3 antibody and mounted using mounting media containing DAPI. Images were taken at 630x 



























Figure 19 - Quantification of LC3 puncta in thiopurine treated THP-1 derived 
macrophages during a time course 
(A) - Bar graph representing THP-1 derived macrophages with >6 LC3 puncta during thiopurine 
treatment. LC3 Puncta within 30 cells from each treatment group were quantified. n=1.  
(B) - Bar graph representing THP-1 derived macrophages with >6 LC3 puncta during 8h of thiopurine 
treatment. LC3 Puncta within 30 cells from each treatment group were quantified. One-way anova with 




4.2.4. Autophagy activity of THP-1 derived macrophages treated with a range of 
thiopurine concentrations 
As similar autophagy induction was observed with all three thiopurines at 120μM after 
8h incubation, the effect of lower thiopurine concentrations was examined in an 
attempt to tease out any differences in autophagy induction. A concentration curve 
was performed from a range of 20-120μM of each thiopurine. As shown in Figure 20 
and 23A, AZA treated cells exhibited a small increase of 11% in cells exhibiting >6 
LC3 puncta relative to control during treatment at a concentration of 20μM, which 
increased up to 33% during treatment at a concentration of 120μM. 6-MP and 6-TG 
treated cells exhibited an increase in autophagosome puncta at lower concentrations 
tested, with 20µM exhibiting an increase of 20% and 22% in cells with >6 LC3 puncta 
respectively relative to the control, although this was not significant (Figure 23B). 
Autophagosome accumulation increased by 57% when cells were treated with 6-MP 
at 120μM and 30%% when cells were treated with 6-TG at 120µM relative to the 
control (Figure 21, 22 and 23A). This suggests that autophagosome accumulation is 
concentration dependent and the highest autophagosome accumulation can be 
observed when cells are treated with thiopurines at a concentration of 120µM with all 




































Figure 20 - Fixed cell imaging of immunostained LC3 in THP-1 derived 
macrophages treated with an AZA concentration curve.  
THP-1 derived macrophages were either treated with DMSO (Control), serum starved (SS) or treated 
with 20-120μM AZA and incubated for 8h at 37oC / 5% CO2. Samples were fixed, immunostained using 
LC3 antibody and mounted using DAPI mounting media. Images were taken at 630x magnification 




























Figure 21 - Fixed cell imaging of immunostained LC3 in THP-1 derived 
macrophages treated with a 6-MP concentration curve.  
THP-1 derived macrophages were either treated with DMSO (Control), serum starved (SS) or treated 
with 20-120μM 6-MP and incubated for 8h at 37oC / 5% CO2. Samples were fixed, immunostained using 
LC3 antibody and mounted using DAPI mounting media. Images were taken at 630x magnification 





























Figure 22 - Fixed cell imaging of immunostained LC3 in THP-1 derived 
macrophages treated with a 6-TG concentration curve.  
THP-1 derived macrophages were either treated with DMSO (Control), serum starved (SS) or treated 
with 20-120μM 6-TG and incubated for 8h at 37oC / 5% CO2. Samples were fixed, immunostained using 
LC3 antibody and mounted using DAPI mounting media. Images were taken at 630x magnification 























Figure 23 - Quantification of LC3 puncta in THP-1 derived macrophages treated 
with a thiopurine concentration curve. 
(A) - Bar graph representing THP-1 derived macrophages with >6 LC3 puncta during 20-120μM 
treatment of thiopurines. LC3 Puncta within 30 cells from each treatment group were quantified. n=1. 
(B) - Bar graph representing THP-1 derived macrophages with >6 LC3 puncta during 20μM treatment 
of thiopurines. LC3 Puncta within 30 cells from each treatment group were quantified. A one-way 




4.2.5. Sustained autophagy induction in response thiopurine treatment.  
Sustained autophagy induction was observed during a 24h incubation in HEK293 cells 
treated with thiopurines at 120μM. We therefore treated THP-1 derived macrophages 
with thiopurines for 24h to determine if a similar response was observed in the IBD 
relevant cell line. As shown on Figure 24, a sustained autophagy induction can be 
observed in all thiopurines tested. A significant increase in 31% of cells >6 LC3 puncta 
was observed during AZA and 6-TG treatment. The highest response was seen within 
6-MP treated THP-1 derived macrophages, with a 35% significant increase in cells >6 
LC3 puncta relative to the control (Figure 25). These results confirm autophagy 










































Figure 24 - Fixed cell imaging of Immunostained LC3 in THP-1 derived 
macrophages treated for 24h with thiopurines.   
THP-1 derived macrophages were either treated with DMSO (Control), serum starved (SS), treated with 
120μM AZA, 120μM of 6-MP, or 120μM of 6-TG. THP-1 derived macrophages were then incubated for 
24h at 37oC / 5% CO2 with the pharmaceutical agent. Samples were fixed, immunostained using an 
anti-LC3 antibody and mounted using DAPI mounting media. Images were taken at 630x magnification 
























Figure 25 - Quantification of LC3 puncta in THP-1 derived macrophages treated 
for 24h with thiopurines.  
Bar graph representing THP-1 derived macrophages with >6 LC3 puncta during thiopurine treatment. 
LC3 Puncta within 30 cells from each treatment group were quantified. A one-way ANOVA with Tukey 


























































4.2.6. Activation of autophagy by thiopurines  
An accumulation of autophagosomes does not necessarily signify the activation of 
autophagy, as an accumulation can also occur due the inhibition of the lysosome to 
autophagosomes (Mizushima et al., 2010). Therefore, a GFP-RFP-LC3 plasmid was 
utilised to verify the formation of autophagolysosomes, which would confirm the 
completion of autophagy. With this method, the GFP fluorophore is quenched during 
the formation of the autophagosolysosome, due to the acidic nature of lysosomes.  
Therefore, autophagolysosomes will fluoresce red within a transfected cell line, while 
cells within the intermediate stage of autophagosome formation will fluoresce both 
green and red. As indicated in Figure 26, thiopurine treatment increased the formation 
of autophagolysosomes within the cell, with AZA (Figure 26, panel xvii), 6-MP 
(Figure 26, panel xxii) and 6-TG (Figure 26, panel xxvi) increasing the number of 
RFP puncta by 37%, 22% and 21% respectively compared to the DMSO carrier control 
(Figure 27B). This demonstrates that all thiopurines can induce autophagy activity in 






































Figure 26 - THP-1 macrophages transiently transfected with GFP-RFP-LC3 
plasmid to assess thiopurine-induced autophagy activation.  
Representative images of thiopurine treated THP-1 macrophages transfected with a GFP-RFP-LC3 
Plasmid. THP-1 cells were differentiated, transfected with a GFP-RFP-LC3 plasmid using nucleofection 
and were either left untreated (Control), serum starved (SS) or treated with 2µM of DMSO, 120µM of 
AZA, 120µM of 6-MP and 120µM of 6-TG for 8 hours. Cells were also treated with 160nm of bafilomycin, 
which would induce autophagosome accumulation by inhibiting autophagosome-lysosome fusion. 
Samples were fixed, immunostained using LC3 antibody and mounted using DAPI mounting media. 
Images were taken at 630x magnification using a Carl Zeiss LSM880 confocal microscope. Images 

























Figure 27 - Quantification of thiopurine-induced autophagy induction in GFP-
RFP-LC3 transfected THP-1 derived macrophages.   
 (A) - Bar graph representing GFP-RFP-LC3 transfected THP-1 derived macrophages with >8 LC3 
puncta during thiopurine treatment. LC3 Puncta within 10 cells from each treatment group were 
quantified. n=2. 
(B) - Bar graph representing number of RFP-LC3 puncta within GFP-RFP-LC3 transfected thiopurine 
treated THP-1 macrophages. RFP-LC3 Puncta within 10 cells from each treatment group were 




4.2.7. The effects of thiopurines on apoptosis 
Due to the relationship in signalling pathways between autophagy and apoptosis, we 
examined the effect of thiopurines on both the early and late stages of apoptosis. An 
Annexin-V/PI stain can differentiate between the early and late stages of apoptosis 
due to the availability of markers for apoptosis at the different stages of the pathway. 
Annexin V can bind to phosphatidylserine (PS) with high affinity, which becomes 
exposed on the outer leaflet of the plasma membrane during early stage apoptosis. 
Due to the permeabilisation or rupturing of the membrane that that can occur in cells 
during late apoptosis or necrosis, the DNA-binding molecule, (PI), can enter the cell 
and bind to DNA. Therefore, healthy cells (Annexin-V-/PI-), cells in early apoptosis 
(Annexin-V+/PI-) and those in the late stages of apoptosis or necrosis (Annexin-V+/PI+) 
can be differentiated. As shown on Figure 28, AZA and 6-TG treated cells exhibited a 
decrease in healthy cells, with AZA and 6-TG treated cells exhibiting a decrease of 
15.4% and 10.6% respectively relative to the DMSO-treated control (Figure 29). 
Treatment with 6-MP resulted in a similar percentage of healthy cells compared to the 
DMSO-treated control. An increase in early apoptosis was observed in both AZA and 
6-TG treatment, with an increase of 11.2% and 7.5% in Annexin-V+/PI- cells relative to 
the DMSO-treated control (Figure 29). A minor increase of 4.6% and 2.9% in Annexin-
V+/PI+ cells was observed during AZA and 6-TG treatment relative to the DMSO-
treated control (Figure 29). These results would suggest that AZA and 6-TG induce 


































Figure 28 (i-vi) – Annexin V/PI staining utilising flow cytometry in thiopurine 
treated THP-1 macrophages.  
THP-1 derived macrophages were either left untreated (i), treated with DMSO (ii), 120µM of AZA (iii), 
120µM of 6-MP (iv), 120µM of 6-TG (v) or deionised H20 (vi). Cells were stained using an Annexin-V kit 


















































Figure 29 - Quantification of Annexin V/PI staining in thiopurine treated THP-1 
macrophages.  
THP-1 derived macrophages were either left untreated (i), treated with DMSO (ii), 120µM of AZA (iii), 
120µM of 6-MP (iv), 120µM of 6-TG (v) or deionised H20 (vi). Cells were stained using an Annexin-V 
kit and PI solution and were analysed by flow cytometry. Mean percentage population from each 
quadrant was quantified. Each treatment was performed in duplicate. n=1. 
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4.3. Summary  
Initially, differentiation of THP-1 cells with PMA was assessed through the adherence 
of cells to the dish and it was concluded that 20ng/ml was the most effective 
concentration. Flow cytometric analysis of CD68, CD163 and CD80 surface marker 
expression indicated that differentiation with PMA using 20ng/ml did not polarise cells 
into an M1 or M2 state.  
Utilising a thiopurine time-course, the highest autophagosome accumulation was 
observed at the 8h time point. Interestingly, 6-MP produced the highest 
autophagosome accumulation in comparison to all thiopurines tested. Furthermore, 6-
MP and 6-TG induced a slight increase in autophagosome accumulation at low 
concentrations when compared to AZA and control cells, however this was non-
significant. All thiopurines also induced autophagosome accumulation for up to 24h, 
indicating that autophagy induction is sustained during thiopurine treatment.  
Utilising a GFP-RFP-LC3 plasmid, results demonstrate that activation of autophagy 
occurs in response to all thiopurines tested. Due to the interconnection of autophagy 
and apoptotic pathways, an Annexin V/PI Stain was performed to determine whether 
autophagy activation occurs independent of apoptosis. An increase in early apoptosis 
was observed in AZA and 6-TG treated cells, in contrast to 6-MP, which did not show 
an increase in cells undergoing early apoptotic signalling. 
Taken altogether, these results suggest that all thiopurines induce autophagy activity 
in which 6-MP showed the highest autophagy induction compared to AZA and 6-TG.  
In addition, AZA and 6-TG also induced early apoptotic signalling whereas 6-MP did 
not. However, results cannot be conclusive as experiments were performed once. 
Therefore, future studies are required to confirm these findings. Further studies are 





Chapter 5. Characterisation of the ER-stress 
and unfolded protein response to thiopurines 
in macrophages 
5.1. Introduction 
Paneth cells are specialised intestinal epithelial cells which produce large amounts of 
host defence peptides to help maintain intestinal barrier integrity (Fritz et al., 2011). 
Increased demand for protein production in Paneth cells also increases susceptibility 
to the accumulation of misfolded proteins within the ER, termed as ER stress (Ma et 
al., 2017). Significantly, the ER stress marker protein BiP is increased in Paneth cells 
and in gut resident-inflammatory cells of patients with IBD, indicating increased ER 
stress (Bogaert et al., 2011).  
Cells have evolved various mechanisms to adapt to unfolded and misfolded proteins 
in the ER; known collectively as the UPR (Ma et al., 2017). As shown in Figure 30, 
the UPR consists of three main signalling pathways which are the PERK-ATF4 
pathway, IRE1α-XBP1 pathway and ATF6 pathway. The importance of the UPR in 
IBD-associated inflammation is highlighted in studies using transgenic mice. For 
example, XBP1 -/- mice, when treated with DSS, develop more severe colitis 
compared to wild-type mice (Kaser et al., 2008b).  
Importantly, studies have shown that the UPR and ER stress response functionally 
intersect with autophagy (Fritz et al., 2011). The UPR activates autophagy as a 
protective mechanism to reduce the burden of protein accumulation and maintain cell 
survival during ER stress (Ogata et al., 2006). Work from Hooper et al., (2019) has 
demonstrated that PERK gene expression is induced during AZA treatment, indicating 
activation of the UPR. Autophagy activity observed in response to AZA treatment was  
diminished in the presence of a pharmacological inhibitor of  PERK , indicating that 
autophagy is activated in part through UPR-dependent mechanisms (Hooper et al., 
2019). In addition, mTORC1, a critical pathway in metabolism and autophagy 
signalling, was found to be inhibited in the response to AZA treatment. However, 
mTORC1 signalling was not altered during the pharmacological inhibition of PERK, 
indicating mTORC1 signalling functions upstream or parallel to PERK signalling. In 
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this chapter, we aimed to further characterise the UPR and ER-stress response to 
thiopurine treatment in THP-1 derived macrophages. We also aim to identify if mTOR 











Figure 30 - The Unfolded Protein Response. 
Author’s illustration of the IRE1α, PERK and ATF6 signalling cascade. IRE1α, PERK and ATF6 are 
activated due to the dissociation of BiP that occurs in the presence of an accumulation of misfolded 
proteins in the ER lumen. (A) IRE1α induces the splicing of XBP1 mRNA which is a potent transcription 
factor that induces transcription of proteins such as EDEM1 and HRD1, proteins part of the ER-
associated degradation pathway that function to remove misfolded proteins with the ER lumen. (B) 
PERK induces the phosphorylation of eif2α, which inhibits global protein translation within the cell. Eif2α 
phosphorylation subsequently induces ATF4 transcription which leads to CHOP transcription. CHOP 
induces the expression of, pro-apoptotic proteins GADD34, ERO1α and the down regulation of anti-
apoptotic markers such as Bcl-2. (C) Activation of ATF6 leads to translocation to the Golgi apparatus 
where it is spliced through site-1 and site-2 proteases and can increase the expression of GRP78 (BiP), 




Hypothesis: Induction of the UPR and autophagy by thiopurines occurs 
independent of ER stress. 
 
Aim 1: Determine whether induction of the UPR response by thiopurines occurs 
independent of the ER stress response. 
Aim 2: Characterise the expression of UPR genes in response to thiopurines. 
Aim 3: Characterise the expression and activity of UPR proteins in response to 
thiopurines. 


















5.2. Results  
5.2.1. Evaluation of the ER stress response to thiopurines in macrophages  
Induction of ER stress is a key event preceding UPR activation (Ma et al., 2017), 
therefore, we investigated whether thiopurines induce ER stress in THP-1 derived 
macrophages. Cells were treated with thiopurines for 8 hrs at 120µM and ER stress 
was assessed via endpoint PCR for XBP1 splicing, an event that occurs during IRE1α 
activation and which is a well characterised marker for ER stress (Figure 30, Part A). 
Tunicamycin, a drug that inhibits N-linked glycosylation resulting in a build-up of 
misfolded protein in the ER, was used as a positive control for ER stress (Kishino et 
al., 2017). As shown in Figure 31, no XBP1 splicing was observed in response to any 
of the thiopurines (Lane 5,7,9), in contrast tunicamycin resulted in clear splicing of 
XBP1 (Lane 3). Two splice variants were observed during tunicamycin treatment 
(Figure 31, Lane 11), which is caused by the formation of a hybrid product that is 
double stranded cDNA consisting of a single strand of XBP1u and a single strand of 
XBP1s (Chalmers et al., 2017). The formation of this hybrid product indicates the 
presence of mild ER stress in the cell and the activation of the IRE1α pathway (Shang 




























Figure 31 - End-point PCR analysis of XBP1 splicing in response to thiopurines.   
THP-1-derived macrophages were either treated with DMSO (Control), 120µM AZA, 120µM 6-MP, 
120µM 6-TG or 5µg/ml Tun for 8 hours. RNA was extracted and converted into cDNA. XBP1 PCR 
products were resolved on a 2% agarose gel containing safeview and analysed using Syngene 
software. Actin PCR products were resolved on a 1% agarose gel and analysed using syngene 
software. RT-ve samples were used to evaluate genomic DNA contamination. DEPC-treated deionised 




5.2.2. Characterisation of UPR gene expression in response to thiopurine 
treatment 
The expression of genes associated with the UPR response were investigated using 
real-time PCR. Surprisingly, expression of PERK was not affected by thiopurines 
(Figure 32, iv), however, the expression of genes downstream of PERK, namely ATF4 
and CHOP increased significantly in response to 6-TG (Figure 32, i and iii). In 
contrast, expression of ATF4 and CHOP were not affected by AZA or 6-MP (Figure 
32, i and iii). Furthermore, the expression of EDEM1 and BiP were not affected by 
any of the thiopurines (Figure 32, ii and v). Positive control, tunicamycin, significantly 
induced the expression of all UPR genes tested. Melt curves analysis showed a single, 
defined, peak in all amplicons tested, indicative of a single amplicon being generated 
as a final product (Figure 33). Together, these results suggest that 6-TG activates 



















Figure 32 (i-v) – Real-time PCR analysis of UPR associated genes in response 
to thiopurines.  
THP-1-derived macrophages were either treated with DMSO (Control), 120µM AZA, 120µM 6-MP, 
120µM 6-TG or 5µg/ml Tun for 8 hours. RNA was extracted and converted into cDNA. cDNA was used 
as a template for qPCR analysis using primers specific for CHOP, EDEM1, ATF4, PERK and BiP. 
Values were normalised to the geometric mean of housekeeper genes ATP5B and RPL13A for 
corresponding treatments and time-points. Fold Change was calculated through the 2-ΔΔCt method. One-
way anova with Dunnett’s multiple comparison was performed comparing ΔCt values for treatment and 




























Figure 33 (i-v) – Melt curves of UPR associated genes in response to thiopurines.  
THP-1-derived macrophages were either treated with DMSO (Control), 120µM AZA, 120µM 6-MP, 
120µM 6-TG or 5µg/ml Tun for 8 hours. RNA was extracted and converted into cDNA. cDNA was used 
as a template for qPCR analysis using primers specific for CHOP, EDEM1, ATF4, PERK and BiP. Melt 





5.2.3. Assessment of Eif2α phosphorylation in response to thiopurine treatment  
In the previous section we observed increased expression of UPR genes downstream 
of PERK in response to 6-TG. As a result of the activation of PERK, Eif2α is 
phosphorylated which causes global protein attenuation and the activation of ATF4 
and CHOP.  We therefore, examined the phosphorylation of eif2a (p-eif2a) at Ser51 
in response to thiopurine treatment. Brefeldin A (BFA) can induce the UPR through 
the inhibition of intracellular vesicle formation and protein trafficking between the ER 
and Golgi apparatus (Colanzi et al., 2013). Therefore, BFA was used as a positive 
control for eif2α phosphorylation (Colanzi et al., 2013).  As shown on Figure 34, 
increased phosphorylated of eif2a (S51) was observed in 6-TG treated cells (Figure 
34A, lane 4) and the positive control, BFA (Figure 34A, lane 5). A small increase in 
eif2α phosphorylation was also observed in response to AZA relative to the control 
group (Figure 34A, lane 1 and 2). No increase in eif2α phosphorylation was observed 
in response to 6-MP treatment. Total eif2α remained unchanged in all treatment 
groups tested relative to the control. Together, these results suggest that AZA and 6-

































Figure 34 - Eif2α phosphorylation in response to thiopurine treatment. 
(A) – THP-1-derived macrophages either treated with DMSO (Control), 120µM AZA, 120µM 6-MP, 
120µM 6-TG or 1µg/ml BFA for 8 hours. Protein lysates were harvested and separated on an 8% SDS-
page gel. Proteins were transferred onto nitrocellulose and immunoblotted using antibodies specific for 
p-eif2α (S51), eif2α and β-actin. Representative images are shown. n=3. 
(B) – Densitometry was performed on  immunoblots using licor software. P-eif2α (S51) mean intensity 




5.2.4. EDEM1 protein expression in response to  thiopurine treatment  
ER resident protein, EDEM1, is a mannose-binding protein involved in  targeting of 
misfolded proteins for proteosomal degradation during ER stress (Zuber et al., 2007). 
As shown in Figure 30, Part A, EDEM1 is thought to be regulated through the IRE1α 
pathway. We therefore assessed changes in the abundance of EDEM1 in response to 
thiopurine treatment. As shown in Figure 35, no change in EDEM1 protein was 
observed in response to any thiopurine treatment, which is in agreement with the real-
time PCR data (Figure 35). Taken together, these results suggest that thiopurines do 










































Figure 35 - EDEM1 protein expression in response to thiopurine treatment. 
(A) - THP-1-derived macrophages either treated with DMSO (Control), 120µM AZA, 120µM 6-MP, 
120µM 6-TG or 1ug/ml BFA for 8 hours. Protein lysates were harvested and separated on an 8% SDS-
page gel. Proteins were transferred onto nitrocellulose and immunoblotted using antibodies specific for 
EDEM1 and β-actin. Density of EDEM1 was normalised to actin using Licor software. Representative 
images are shown. n=2. 
(B) – Densitometry was performed on immunoblots using licor software. EDEM1 mean intensity was 




5.2.5. Modulation of mTORC1 activity in response to thiopurines   
mTORC1 is a key regulator of cell homeostasis and regulates numerous pathways 
including glucose metabolism, protein translation, and autophagy (Xie et al., 2018). 
mTORC1 inhibits autophagy activity during periods of amino acid sufficiency and 
induces autophagy activity during times of amino acid starvation, therefore mTORC1 
activity is inversely correlated with autophagy activity (Rabanal-Ruiz et al., 2017).  As 
shown in Figure 36, control of protein translation by mTORC1 is mediated by its ability 
to directly phosphorylate p70S6 kinase, which subsequently leads to the 
phosphorylation of ribosomal protein S6, a key protein within cap dependent 
translation and ribosomal biogenesis (p-rpS6) (Magnuson et al., 2012). Therefore, we 
measured p-rpS6 (S235/S236) as a surrogate marker of mTORC1 activity. As shown 
in Figure 37B, AZA decreased the levels of p-rpS6 by 43% relative to total rpS6 
(Figure 37A, Lane 1 and 2). In contrast, 6-MP and 6-TG reduced phosphorylation by 
6% compared to total rpS6 (Figure 37A, Lanes 1, 3 and 4). Unexpectedly, serum 
starvation induced only a moderate decrease of 24% in phospho-S6 ribosomal protein 
relative to total rpS6 (Figure 37A, Lane 1 and 5). Total rpS6 protein expression 
remained unchanged in all treatment groups tested relative to the control. Taken 
together, these results suggest that, AZA can strongly inhibit mTORC1 activity 




































Figure 36 - mTORC1 signalling pathway. 
Author’s illustration of the signalling events associated with mTORC1 activation. (A) mTORC1 
phosphorylates ULK1 and ATG13 at amino acids S757 and S258, respectively, which subsequently 
incorporates within the ULK-ATG13-FIP2000 complex, inhibiting autophagy. (B) mTORC1 induces the 
phosphorylation of S6K1 at amino acid T389, which subsequently phosphorylates S235/236 on 
ribosomal protein S6 and induces mRNA biogenesis, lipid synthesis and cap dependent elongation and 
translation. (C) mTORC1 phosphorylates amino acids T37/46, T70 and S5 on protein 4E-BP1, inhibiting 
its binding to eIF4E. This allows eiF4E to induce Cap-dependent translation. Illustration was created 


























Figure 37 - Modulation of mTORC1 activity in response to thiopurine treatment. 
(A) – THP-1-derived macrophages were either treated with DMSO (Control), 120µM AZA, 120µM 6-
MP, 120µM 6-TG or serum starved for 8 hours. Protein lysates were harvested and separated on a 
10% SDS-page gel. Protein was transferred onto nitrocellulose and immunoblotted using antibodies 
specific for p-rpS6 (S235/236), total-rpS6 and β-actin. Density of p-rpS6 (S235/236) was normalised to 
total-rpS6 using Licor software. western immunoblot is shown as a representative image. n=2. 
(B) – Densitometry was performed on  immunoblots using licor software. P-rpS6 (S235/236) mean 





Initially, splicing of ER stress marker XBP1 was examined to determine whether 
thiopurines activate the ER stress response. XBP1 signalling was not increased in 
response to all thiopurines tested, indicating that thiopurines do not induce ER stress 
signalling. 
At the 8h time-point, 6-TG significantly induced the expression of PERK downstream 
signalling genes, ATF4 and CHOP. An increase in the phosphorylation of the 
downstream PERK substrate, eif2α, was also observed during 6-TG treatment, 
confirming the activation of PERK signalling by 6-TG. No increase was observed in all 
UPR genes tested in response to both AZA and 6-MP treatment. However, a slight 
increase in eif2α phosphorylation was observed in response to AZA treatment, but not 
6-MP treatment. IRE1α signalling appears to be not regulated by thiopurine treatment 
as EDEM1 gene and protein expression was not altered in response to all thiopurines.  
The activity of mTORC1 was analysed to determine whether thiopurines regulate 
autophagy through mTORC1 signalling. AZA markedly decreased rpS6 
phosphorylation indicating a decrease in mTORC1 activity. In contrast, 6-MP and 6-
TG exhibited no change in rpS6 phosphorylation. 
Taken together these results suggest 6-TG induces PERK signalling at the time and 
dose assessed. AZA inhibits mTORC1 activity, which was not observed in 6-MP and 











Chapter 6. Discussion 
6.1. Overview 
IBD treatment in the UK costs approximately £720 million per year, with 25% of this 
being associated with drug costs (NHS England). 1 in 5 UC patients have ineffective 
response rates and 60-75% of CD patients require surgery due to the ineffectiveness 
of treatment (nhs.uk, 2018). Therefore, it is important to identify the interaction of these 
drugs with pathways associated with IBD so that therapies can be more appropriately 
optimised. The immunosuppressive capabilities of thiopurines have been found to be 
beneficial for the treatment of IBD, for example in post-operative disease maintenance, 
prolonging disease remission and regulation of antibody production when used in 
conjunction with TNF-α therapy (Axelrad et al., 2016). However, thiopurines have been 
scrutinised due to their extensive side effects, including hepatotoxicity, pancreatitis 
and myelotoxicity, which limit their capabilities (Qiu et al., 2015). SNPs associated 
directly, and indirectly, with genes involved in the autophagy pathway have been linked 
to the pathogenesis of IBD (Massey et al., 2008). Interestingly, previous work by 
Hooper et al., (2019) found that thiopurines regulate autophagy activity. We therefore 
aimed to further characterise the regulation of autophagy activity by thiopurines. 
6.2. HEK293 cells: A reporter cell line for autophagy modulation 
Two types of methodologies can be utilised to investigate autophagy; experiments can 
either observe the presence and movement of autophagy-related proteins or can 
quantify proteins that are degraded through autophagy (Yoshii and Mizushima, 2017). 
LC3 was selected as a marker for autophagy activity due to its close association to 
autophagosomal membranes (Hansen and Johansen, 2011). This is due to the 
specific cleavage that occurs at the carboxyl terminal on LC3 proteins that forms LC3-
I. This allows an exposed glycine group within the carboxyl terminal to conjugate to 
PE on autophagosomal membranes, forming LC3-II (Hansen and Johansen, 2011). 
HEK293 cells are renowned for their robustness, rapid division rate and high DNA 
plasmid transfection efficiency (Ooi et al., 2016). In addition, the autophagy pathway 
is well characterised in HEK293 cells (Musiwaro et al., 2013). HEK293 cells 
engineered to stably express GFP-LC3 were available in our laboratory. This tool 
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allowed us to observe autophagy induction in response to thiopurines in real-time, 
which allowed for more accurate optimisation of drug concentrations and timepoints 
prior to moving our investigation into THP-1 macrophages. Therefore, initial 
experiments, such as assay optimisation, was performed in HEK293 cells and 
validated experimental findings were performed in THP-1 macrophages, due to the 
involvement of immune cells in IBD pathogenesis. 
6.3. Induction of autophagy by thiopurines in HEK293 cells 
Hooper et al., (2019) demonstrated that concentrations of AZA at 120µM induced 
autophagy and were not cytotoxic to HEK293 cells. However, 6-MP and 6-TG were 
not investigated. We therefore initially treated GFP-LC3 engineered HEK293 cells with 
AZA, 6-MP and 6-TG at a concentration of 120µM to determine effects on autophagy 
and cytotoxicity. We observed that all thiopurines induced autophagy modulation in 
HEK293 cells. Interestingly, AZA induced autophagosome accumulation more rapidly 
compared to 6-MP and 6-TG. This could suggest that secondary events resulting from 
the metabolism of AZA, including the depletion of GSH, increased ROS production, 
and release of the imidazole derivative may have an effect of autophagy induction.  
ROS has been found to be critical in the induction of autophagy during AZA treatment, 
with ROS scavenging leading to a reduction in apoptosis and LC3-II (Chaabane and 
Appell, 2016). Excessive ROS production caused by AZA treatment results in 
mitochondrial damage and the depletion of ATP through the opening of mitochondrial 
permeability transition pores (Lee & Farrell, 2001). Additionally, Fernández-Ramos et 
al. (2017) found that  6-MP mediated ATP depletion regulated autophagy related 
signalling pathways such as the phosphorylation of AMPK and inhibition of mTORC1. 
Furthermore, moderate ROS concentrations inhibit protein tyrosine phosphatases, 
which can induce (PI3K) signalling, a major pathway involved in autophagy signalling 
(Zhao et al., 2017). This illustrates that ROS produced during the metabolism of 
thiopurines could regulate the primary pathways which directly regulate autophagy 
activity. ROS can be produced from several reactions that take place during the 
metabolism of thiopurines. For example, Al Maruf et al. (2014) found that the depletion 
of GSH was compulsory for ROS formation during AZA treatment. Depletion of GSH 
during AZA treatment is due to the conjugation of reduced GSH to AZA to form 6-MP, 
which is catalysed by glutathione S-transferase. (Al Maruf et al., 2014). 
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In the context of structural modifications to enhance biological activity of these 
therapeutics, the imidazole moiety was initially conjugated to 6-MP to extend the half-
life of the substance as it protects its sulphur group from oxidation and hydrolysis. 6-
MP with the addition of the imidazole moiety was then released as product called AZA, 
which initially showed more therapeutic effects than 6-MP during kidney transplants in 
humans (Murray et al., 1963). As much as 12% of AZA can be metabolised to 
hypoxanthine and imidazole (Fotoohi et al., 2010). Interestingly, imidazole conjugates 
have also illustrated PI3K inhibitory activity (Mohan et al., 2016). If the imidazole 
derivatives that are released during AZA metabolism also exhibited the same inhibitory 
effect towards PI3K, this may explain how AZA could induce autophagy activity more 
rapidly than 6-MP and 6-TG.  
Live cell imaging is an effective method to observe autophagosome accumulation in 
real-time. However, due to stress that is caused by inducing cells to express 
fluorescent proteins, it is difficult to achieve this in sensitive cell lineages. In addition, 
due to GFP being a large protein (28kDa in size and 4.2nm in length), there is the 
possibility that the conjugation of GFP could affect the activity and localisation of LC3 
(Hink et al., 2000). Fixed cell imaging is commonly employed to assess protein 
localisation as it is cost-effective, less time-consuming and easy to use. (Hobro and 
Smith, 2017). PFA is commonly utilised as a fixation agent during fixed cell imaging 
as it causes molecular cross-linking between amino groups of lysine resulting in 
methylene bridge formation, which preserves cellular architecture and bio-active 
molecules within their spatial relationship in the cell (Thavarajah et al., 2012). As both 
techniques utilise different methodologies, we aimed to assess if autophagosome 
accumulation was comparable between fixed cell imaging and live-cell imaging. We 
observed that 6-MP treatment in fixed cells was not in agreement with results from live 
cell imaging, as autophagosome accumulation was not observed in fixed cells during 
an 8h treatment course. Live cell imaging requires that intense light is used to excite 
the fluorophores of interest in the sample, which may result in phototoxicity in live 
samples (Icha et al., 2017). This may explain the induction of autophagy in the control 
group after the 12h timepoint during live cell imaging, which was not observed in fixed 
cell imaging. Therefore, despite live cell imaging being a powerful experimental tool, 
fixed cell imaging may produce more reliable results. 
112 
 
Using fixed cell imaging, we concluded that all thiopurines were shown to have 
sustained autophagosome accumulation at the 24h time point, indicating a prolonged 
response. Although 24h was the longest time point investigated, results from 
Fernández-Ramos et al. (2017) observed autophagy induction at both a 48h and 72h 
time point during 6-MP treatment in Jurkat T cells, indicating thiopurine induced 
autophagy activity is a more prolonged response than what was observed in our study.  
Thio-GTP has been found to be at concentration of 2.5mM in leukaemia cells after a 
4-hour exposure to 6-TG at 25µM (Shi et al., 1998). The increased concentration of 
Thio-GTP inside the cell during 6-TG treatment found in the study by Shi et al., (1998) 
correlates with the rate at which 6-TG induced autophagy found in our study, indicating 
that the intercalation of thio-GTP into DNA may induce autophagy. The potential 
mechanism is supported by findings from Zeng et al., (2007) who observed that 
HCT116 cells which possess dysfunctional DNA mismatch repair (MMR) systems 
failed to induce autophagy after 3 days of 6-TG treatment, in contrast to MMR+ cells, 
which did induce autophagy. Therefore, a potential mechanism of autophagy induction 
could be due to the incorporation of drug metabolites into DNA and could be facilitated 
by metabolites released during the catabolism of thiopurines, which also could explain 
the differences in the rate of autophagy induction.  
6.4. Effect of thiopurines on the metabolic activity of HEK293 cells  
Our results illustrated that 6-TG has a more anti-proliferative effect than AZA and 6-
MP, which in agreement with previous in vitro studies (Adamson et al., 1994). The 
increased anti-proliferative effect of 6-TG could be due to the direct conversion of 6-
TG to its active substrate, 6-TGN, compared to 6-MP and AZA, which undergo a series 
of enzymatic steps that produce several inactive metabolites (Seinen et al., 2010). By 
avoiding many rate limiting enzymatic steps, particularly IMPDH, this allows 6-TG to 
be rapidly converted into 6-TGN. Significantly higher concentrations of 6-TGN have 
been found to be generated from 6-TG treatment compared to AZA and 6-MP due to 
increased bioavailability (Petit et al., 2008). Shi et al., (1998) demonstrated that 6-TG 
treated leukaemia cells, observed over a 24h period, had a higher accumulation of 
thio-GMP, GDP and GTP compared to 6-MP treated cells. This is reinforced by 
findings that the drug becomes undetectable in patient plasma 6 hours post-
administration (Blaker et al., 2012). Therefore, it appears that 6-TG may have a more 
potent anti-proliferative effect compared to AZA and 6-MP due to producing a higher 
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concentration of metabolites that can intercalate into DNA. We observed a reduction 
in metabolic activity at the 2h timepoint and an increase in autophagy activity at the 4h 
timepoint in response to 6-TG treatment. Therefore, it could be speculated that the 
increase in autophagy activity is a survival mechanism responding to a decrease in 
metabolic activity. However, AZA and 6-MP also showed an increase in autophagy 
activity without observed changes to metabolic activity, indicating that the mechanisms 
may be independent.  
6.5. THP-1 cells: An in vitro cell model of macrophage function 
A dysregulation in the immune response is one of the key factors associated with IBD 
pathogenesis. The inability for gastrointestinal macrophage’s to clear invading 
pathogens and an imbalance of pro-inflammatory to anti-inflammatory signalling has 
been found facilitate IBD development (Steinbach and Plevy, 2014). Therefore, we 
aimed to validate experimental findings in an in vitro macrophage model. The 
monocytic cell line, THP-1 cells, are the most commonly used cell line for in vitro 
studies investigating human macrophage function (Lund et al., 2016). They can be 
differentiated into a variety of macrophage subsets (Starr et al., 2018). PMA is a well-
documented phorbol ester that can differentiate monocytes to macrophages through 
the activation of protein kinase C (Schwende et al., 1996). However, there is no gold-
standard protocol for the differentiation of THP-1 cells into macrophages, and 
concentrations of PMA used range from 6 to 500nM throughout the published literature 
(Lund et al., 2016). Studies have found that higher concentrations of PMA can 
stimulate the expression of inflammatory genes, such as IL-8, TNF-α and IL-1β (Park 
et al., 2007). Given that exogenous TNF-α has been shown to induce autophagy (Yuan 
et al., 2018), lower concentrations of PMA were investigated for their ability to 
differentiate THP-1 monocytes to avoid autophagy induction from the differentiation 
process. Concentrations of PMA between 5-20ng/ml have been used in numerous 
studies due to their ability to stimulate differentiation of cells which retain common 
macrophage markers and response to stimuli (Lund et al., 2016; Starr et al., 2018). 
PMA at a concentration of 20ng/ml resulted in the highest level of adherence in THP-
1 cells, and therefore this concentration of PMA was used to differentiate THP-1 cells 
for the entirety of this study. 
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Analysis of established macrophage markers was performed to determine whether 
PMA treatment successfully differentiated THP-1 cells into a macrophage-like cell 
phenotype. CD68 is a commonly used marker to identify a variety of different 
macrophage lineages (Chistiakov et al., 2017). An increase in CD68 expression was 
observed in THP-1 monocytes differentiated only with PMA relative to the control. This 
suggests that the PMA treatment used in our study is able to differentiate monocytes 
to macrophages. Although the increase was relatively limited, this could be explained 
by the nature of the protein, which is mainly found in the endosomal/lysosomal 
compartment of the cell (Chistiakov et al., 2017). Approximately 85-90% of murine 
CD68 is located within intracellular pools that can rapidly transfer to the cellular 
membrane (Kurushima et al., 2000). As the cells utilised in this study were not 
permeabilised prior to PMA treatment, this could explain the lack of considerable 
increase in CD68 expression.  
Interestingly the M2 macrophage marker, CD163, was increased in THP-1 monocytes 
treated with PMA. Questions have been raised on the specificity of CD163 in terms of 
M2 macrophages, with prognostic studies in Hodgkin lymphoma exhibiting high 
numbers of CD163+ macrophages within a tumour microenvironment showing a Th1 
signature (Barros et al., 2012). This could also explain the observation of high CD163+ 
marker expression in monocytes treated with LPS and IFN-γ, stimuli know to 
differentiate monocytes to M1 macrophages (Orecchioni et al., 2019).  However, 
monocytes treated with PMA did not exhibit as high as an expression of CD163 
compared to monocytes treated with IL-4 and IL-13, stimuli known to induce M2 
macrophage differentiation. Therefore, the difference in marker expression between 
PMA-only treated THP-1 monocytes and THP-1 derived M1 and M2 macrophage used 
as positive controls would suggest that PMA does not drive THP-1 cells into a M1 or 
M2 subset.  
6.6. Induction of autophagy by thiopurines in THP-1 derived 
macrophages 
Using timepoints and concentrations optimised from findings in HEK293 cells, we 
investigated autophagy induction in response to thiopurines in THP-1 macrophages. 
Fixed THP-1 derived macrophages and HEK293 cells exhibited differences in the rate 
of autophagy induction following 6-MP treatment, with THP-1 derived macrophages 
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exhibiting an induction at the 8h timepoint compared to HEK293 cells, which did not. 
Interestingly, the rate at which thiopurines intercalate into DNA has been found to be 
cell type dependent. For example, after an 48h incubation with 1µM of 6-TG, 0.3% of 
guanine in nuclear DNA was substituted in HCT116, whereas this was two-fold higher 
in J774.a cells (Daehn et al., 2011). However, the induction of autophagy observed 
may not be solely due the incorporation of 6-TGN in DNA, as MMR deficient leukaemia 
cells are also sensitive to thiopurine drugs (Zhang et al., 2013). 
Hepatoxic metabolites produced during the catabolism of thiopurines may induce 
autophagy. As discussed previously, autophagy is increased during thiopurine-
induced hepatotoxicity to protect hepatocytes from the deleterious effects of 
thiopurines (Guijarro et al., 2012). Bradford and Shih, (2011) demonstrated that 
elevated concentrations of 6-MMP in erythrocytes is associated with hepatoxicity in 
patients; indicating 6-MMP may potentially regulate autophagy activity. TPMT is 
responsible for the conversion of thiopurines into inactive S-methyl derivatives, 
including 6-MMP (Cuffari, 2006). TPMT has also been directly associated with 
thiopurine efficacy, with findings in CCRF-CEM cells showing elevations of TPMT 
activity result in an increase in 6-MP sensitivity but a decrease in 6-TG sensitivity 
(Fotoohi et al., 2010). TPMT has been found to have trimodal distribution from patient 
to patient due to autosomal dominant inheritance of polymorphisms associated with 
the enzyme (González-Lama and Gisbert, 2016). This results in patients varying from 
low to high TPMT enzyme activity (González-Lama and Gisbert, 2016). Therefore, it 
would be of value to examine differences in TPMT activity in THP-1 macrophages and 
HEK293 cells to determine its association with thiopurine-induced autophagy activity. 
Increased autophagy activity seen during 6-MP treatment compared to AZA and 6-TG 
could be due to the catabolism of 6-MP to meTIMP. meTIMP is an inhibitor of 
phosphoribosylpyrophosphate amidotransferase, an enzyme critical for the initial 
stages of de novo purine biosynthesis (Karran, 2007). This can result in purine 
starvation in the cell, which may ultimately lead to metabolic stress and autophagy 
induction (Karran, 2007). This mechanism of action would only be applicable towards 
AZA and 6-MP, as 6-TG is not catabolised to form thioinosine monophosphate.  
In addition, the metabolism of 6-MP to thiouric acid by xanthine oxidase is also a 
reaction known to produce ROS (Chaabane and Appell, 2016). Therefore, ROS 
produced during the metabolism of 6-MP to thiouric acid could result in an increase in 
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autophagosome accumulation observed. Interestingly, HEK293 cells do not express 
xanthine oxidase, which could explain the difference in autophagy induction observed 
between 6-MP-treated HEK293 cells and THP-1 derived macrophages (Haglund et 
al., 2017). However, studies have suggested ROS production is not a critical factor in 
the mechanism of action as AZA treatment in human hepatocytes had shown to only 
slightly increase ROS production (Petit et al., 2008). It was speculated that excessive 
ROS production by 6-TG and 6-MP may be restricted to tumour cell lines (Chaabane 
and Appell, 2016). In addition, Petit et al., (2008) observed an increase in ROS 
production in 6-TG-treated cells only after 96h. Therefore, next steps should attempt 
to identify if ROS production during thiopurines treatment is sufficient to induce 
autophagy in non-tumour cells. This could be assessed by inhibiting ROS production 
through the use of antioxidants, including N-acetylcysteine, and assessing autophagy 
induction during the use of these agents. ROS production could be examined through 
the use of 2’, 7’ dichlorofluorescein diacetate. Dichlorofluorescein is a substrate that 
is oxidised by intracellular ROS, which produces as fluorescent dichlorofluorescein 
and can be measured through spectrophotometry (Al Maruf et al., 2014). 
We also observed a dose-dependent increase in autophagosome accumulation when 
concentrations of thiopurines between 20-120µM were tested. A slight increase in 
autophagosome accumulation was observed during treatment with 20µM of 6-MP and 
6-TG compared to AZA, suggesting that catabolism of AZA is not the primary 
mechanism for autophagosome accumulation; however, these results were non-
significant. These results may also suggest that the release of the imidazole derivative 
may inhibit AZA induced-autophagy activity. Imidazole has been shown to inhibit 
autophagy by impairing maturation of autophagosomes to lysosomes (Liu et al., 2015). 
It has been proposed that this is due to imidazole being a weak base, which can enter 
acidic organelles and cause dysfunction by elevated intra-lysosomal pH (Liu et al., 
2015). Imidazole has also been shown to increase apoptosis inside HEC-1B cells, with 
an increase in pro-apoptotic markers Bim, caspase 3 and caspase 9 (Liu et al., 2015). 
This potentially could explain why three quarters of IBD patients intolerant to AZA 
treatment respond more effectively to 6-MP treatment (McGovern et al., 2002). One 
challenge when utilising in vitro tools is the translation of therapeutic concentrations of 
drugs to and from in vivo research. The concentrations used in this study were 
selected due to the use of these concentrations in previous studies and lack of 
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cytotoxicity observed from metabolic assays (Chaabane and Appell., 2016; Hooper et 
al., 2019). Lennard et al., (1997) suggested that drug concentrations are not likely to 
surpass 10µM within tissue when a dose of 2-3mg/kg is administered. However, we 
did not observe a sustained loss of metabolic activity or late apoptosis signalling in the 
highest dose used within this study, indicating that the concentration used were of 
physiological relevance.  
6.7. Effect of thiopurines on autophagy activity in THP-1 derived 
macrophages 
We analysed the accumulation of LC3-II as this protein accumulates on 
autophagosome membranes inside the cell. However, LC3-II abundance does not 
directly correlate with autophagy activity, as an increase in LC3-II can also result from 
the inhibition of autophagosome fusion and degradation by lysosomes (Yoshii et al., 
2017). It was therefore critical that we distinguished if the increased autophagosome 
accumulation that we observed in response to thiopurines was due to activation or 
inhibition of the autophagy pathway. To elucidate if autophagy was activated during 
thiopurine treatment, we utilised a GFP-RFP-LC3 plasmid. We observed an increase 
in autophagic puncta (RFP+/GFP-) in response to thiopurines, indicating the complete 
progression of the autophagy pathway.  As autophagy is found to be dysfunctional in 
IBD patients, the findings that autophagy is induced during thiopurine treatment could 
help partially explain its mechanism of action. The induction of autophagy has been 
shown be therapeutic in CD patients. Rapamycin, an mTOR inhibitor and inducer of 
autophagy, has been found to improve disease symptoms in CD patients (Massey et 
al., 2008). Moreover, rapamycin has been found to induce clinical remission and 
mucosal healing in refractory paediatric CD patients (Mutalib et al., 2014). These 
findings help support the theory that the induction of autophagy by thiopurines could 
be therapeutic in IBD patients.  
As shown in Figure 38, the induction of autophagy activity by thiopurines could have 
a range of benefits in IBD patients. For example, Andrographolide, a known mitophagy 
inducer, has been shown to inhibit the NLRP3 inflammasome and reduce DSS-
induced colitis (Larabi et al., 2020). In addition, autophagy has been found to regulate 
the secretion of the pro-inflammatory cytokine, IL-1β, through the degradation of pro-
IL1β in a NLRP3 and TRIF-dependent manner (Figure 38) (Harris et al., 2011).  
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A common characteristic found in IBD is microbial dysbiosis, which leads to an 
increase in opportunistic pathogens; including AIEC (Vazeille et al., 2015). Autophagy 
is critical in regulating AIEC persistency and the pro-inflammatory cytokines released 
in response to AIEC infection (Small et al., 2013).  AIEC has been shown to be 
persistent in human cell lines by suppressing autophagy, through the induction of 
microRNA MIR106B and MIR93, indicating the importance of functional autophagy in 
AIEC clearance (Lu et al., 2014). In addition, human primary macrophages that 
express the ATG16L1T300A variant exhibit impaired mitophagy, an increase in ROS 
production and ineffective bacterial clearance during Salmonella Typhimurium 
infection (Zhang et al., 2017). Hooper et al., (2019) demonstrated that AZA-treated 
cells exhibited both an increase in autophagy activity and enhanced clearance of 
intracellular AIEC compared to a control group. AIEC-infected THP-1 macrophages 
also exhibited a decrease in TNF-α gene expression when treated with AZA, indicating 
a decrease in the inflammatory response associated with bacterial clearance (Hooper 
et al., 2019). It has also been hypothesised that the binding of ATG16L1 to NOD2 
during bacterial invasion shifts the response towards autophagy signalling, and a 
suppression of functional ATG16L1 leads to a shift towards pro-inflammatory cytokine 
production (Plantinga et al., 2011). This hypothesis is supported by the isolation of 
macrophages and DC’s from the mesenteric lymph nodes in ATG16L1-deficient mice, 
which exhibited an increase in pro-inflammatory cytokines IL-1β and TNF-α (Zhang et 
al., 2017). This could help explain the synergistic effect observed in AZA and anti-
TNFα therapy in IBD patients. In addition, autophagy activation enhances the 
processing of antigens to be presented on MHC I and MHC II molecules and drives 
plasma cells differentiation, which induces the adaptive immune response against 
opportunistic pathogens (Figure 39) (Jiang et al., 2019). Autophagy has also been 
found to play a central role in CD4+ T cell stability, as ATG7-deficient Treg cells exhibit 
a reduction in Foxp3, Foxo and Bach2 which is accompanied by an increase in IFN-γ 
and IL-17 production (Jacquin and Apetoh, 2018). Therefore, thiopurines could induce 
autophagy activity that is otherwise impaired in immune cells harbouring the ATG16L1 
variant, which could promote bacterial clearance, cytokine and ROS regulation that is 





Figure 38 – Autophagy activation in Macrophages.  
Illustration of the impact autophagy induction would have on macrophage’s dysfunctional in autophagy 
signalling. Dysfunctional autophagy in macrophages (left) leads to bacterial persistence, reduced MHC 
presentation, reduced regulatory T cell stimulation and an increase in proinflammatory cytokines 
including IL-1β, TNF-α, IL-6 and IL-18. An induction of autophagy inside macrophages (right) leads to 
an increase in pathogen clearance, MHC presentation and regulatory T-cell stability. It would also 
increase the degradation of pro-IL-1β, leading to a reduction in the release of IL-1β. Image created on 
Biorender software. 
6.8. Interplay between autophagy and apoptosis  
Numerous studies have observed autophagy signalling accompanied with pro-
apoptotic signalling during thiopurine treatment (Chaabane and Appell, 2016; Tiede et 
al., 2003; Zeng et al., 2007). Autophagy has been suggested to play a protective role 
during the induction of apoptosis in hepatocytes (Chaabane and Appell, 2016). We 
observed a slight increase in THP-1 macrophages undergoing early apoptotic 
signalling during AZA and 6-TG treatment. However, statistical significance was not 
established due to a lack of replicates. An increase in apoptotic signalling has 
previously been documented during thiopurine treatment. Tiede et al., (2003) also 
observed an increase in early apoptotic signalling during thiopurine treatment using 
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an Annexin V/PI stain. Although the authors observed apoptotic signalling during 6-
MP treatment, the treatment method was significantly longer, with cells exposed to 
thiopurines for up to 5 days (Tiede et al., 2003). This could strengthen the hypothesis 
that thiopurine-induced autophagy may coincide with apoptotic signalling. Consistent 
with this hypothesis, suppression of autophagy by chloroquine during thiopurine 
treatment increased PARP cleavage (apoptotic marker) in a dose dependant manner 
(Chabbane and Appell, 2016). A colocalization of LC3-II fluorescence and the 
mitochondrial marker, tetramethylrhodamine methyl ester, was also observed, 
indicative of damaged mitochondria being degraded through mitophagy. Tiede et al., 
(2003) also provided evidence that thiopurine-induced apoptosis is dependent of 
mitochondrial injury, as mitochondrial membrane potential was reduced during 6-MP 
treatment and chemical inhibition of caspase 9 activity prevented 6-MP dependent 
apoptosis. Caspases are synthesised as precursors, which can be activated through 
the release of pro-apoptotic markers from the mitochondrial intermembrane space 
during mitochondrial permeabilization (Costantini et al., 2002; Tiede et al., 2003). An 
example of these markers includes cytochrome c, which initiates the formation of the 
apoptosome. One constituent of the apoptosome is pro-caspase 9, which is known to 
play a critical role in 6-MP dependent apoptosis (Costantini et al., 2002). These results 
indicate that the apoptotic signalling observed in our study could be due to 
mitochondrial injury, which could initiate autophagy as a survival mechanism. This 
could be investigated further following a similar approach to Tiede et al., (2003), in 
which markers of apoptosis that are release from injured mitochondria are measured. 
These markers, including pro-caspase 9, could then be regulated by chemical 
inhibition to examine their effect on autophagy signalling and localisation.  
Early apoptotic signalling and autophagy induction observed in our study may also be 
a response to MMR processing caused by base pairing of 6-TGN in DNA, which 
resembles replication errors and drives apoptotic signalling by impairing the activity of 
enzymes involved with DNA replication and repair, such as Topoisomerase II and T4 
DNA Ligase. (Misdaq et al., 2015). (Zeng and Kinsella, 2007) shown evidence of an 
induction of autophagy in a p53 dependent manner during 6-TG treatment, which was 
not observed in MMR-deficient human tumour cells. This mechanism of action would 
be possible in THP-1 macrophages and HEK293 cells as both cell lines are MMR 
proficient. Autophagy induction during DNA mismatch damage was also found to 
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inhibit apoptosis, supporting the hypothesis by Chaabane & Appell (2016) and 
strengthening the argument that autophagy and apoptosis are interlinked (Zeng and 
Kinsella, 2007). Although the distinct mechanisms are not elucidated, p53 is an 
important regulator in metabolic checkpoints and cell metabolism (Fernández-Ramos 
et al., 2017). Interestingly, during AZA treatment, energetic stress has been observed 
where AZA can alter glucose and glutamine metabolism. The adaptive changes during 
AZA treatment also corresponded with AMPK activation (Fernández-Ramos et al., 
2017). Therefore, it could be speculated that the alteration in cell metabolism possibly 
caused by p53 could initiate AMPK as an adaptive response, which subsequently 
activates autophagy.    
An increase in apoptotic signalling in immune cells has been found to be promote 
bacterial clearance and mediate pro-inflammatory signalling. Apoptosis prevents the 
initiation of an inflammatory response as it does not allow cytoplasmic content to be 
expelled into the extracellular environment (Lamkanfi and Dixit, 2010). In addition, 
apoptotic cells that are phagocytosed by macrophages do not induce inflammatory 
cytokines and does not induce the differentiation of DC’s into a pro-inflammatory 
subset (Lamkanfi and Dixit, 2010). For example, the exposure of phosphatidylserine 
to the outer leaflet in apoptotic cells has been found to be essential for the engulfment 
of apoptotic cells by macrophages and fibroblasts (Fadok et al., 2001). Therefore, the 
induction of apoptotic signalling by thiopurines would allow macrophages burdened 
with bacterial infection to be cleared in the absence of a pro-inflammatory response, 
similar to what is seen during pyroptosis or necrosis (Lamkanfi and Dixit, 2010). In 
addition, deletion of proteins involved in the extrinsic apoptotic pathways, such as Fas, 
increased the susceptibility to sepsis associated death in mice during Pseudomonas 
aeruginosa infection, indicating its importance in bacterial clearance (Grassmé et al., 
2000). Therefore, the induction of apoptotic signalling seen in our study may be 
beneficial to bacterial clearance in macrophages. 
6.9. Effects of thiopurines on the ER-Stress response in THP-1 
derived macrophages 
XBP1 is a key regulatory protein in UPR signalling, which prevents chronic ER stress 
and the initiation of inflammatory response in multiple cell types (Cao, 2016). XBP1 
splicing is commonly used a marker for IRE1 activation and ER stress signalling (Cao, 
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2016; Kaser et al., 2008).  Interestingly, deletion of XBP1 in a murine model resulted 
in spontaneous enteritis, which was associated with increased ER stress signalling, 
indicating its importance in CD-associated inflammation (Kaser et al., 2008). In 
addition, SNPs located in intron 4 of XBP1 have been significantly associated with IBD 
in a German cohort, indicating the importance of ER stress in IBD pathogenesis (Kaser 
et al., 2008). Thiopurine treatment induces stress in the cell, resulting in mitochondrial 
permeabilization, ROS production and the induction of MMR (Chabbane and Appell, 
2016; Fernández-Ramos et al., 2017).  We therefore investigated whether induction 
of the UPR reported in the study by Hooper et al., (2019) was direct or a secondary 
effect of induction of ER stress by thiopurines. In the presence of ER stress, a 26bp 
fragment from XBP1 mRNA is excised, resulting in the production of a potent 
transcription factor for UPR associated genes, known as sXBP1 (Calfon et al., 2002). 
Therefore, we investigated XBP1 splicing as a marker for the presence of ER stress. 
Splicing of XBP1 mRNA was not observed in all thiopurines tested, compared to the 
positive control Tunicamycin, which exhibited two splice variants.  
Tunicamycin functions as a N-acetylglucosamine transferase, which blocks N-linked 
glycosylation and leads to the accumulation of misfolded proteins (Kishino et al., 
2017). The largest splice variant observed during tunicamycin treatment has been 
observed from previous studies utilising this assay (Chalmers et al., 2017; Shang and 
Lehrman, 2004). Shang and Lehrman (2004) described the variant as a hybrid product 
that is double stranded cDNA consisting of a single strand of XBP1u and a single 
strand of XBP1s, which is formed during the final PCR step. Due to the larger size of 
the hybrid XBP1 variant, it migrates slower down the gel, producing a distinct third 
band (Figure 39) (Chalmers et al., 2017). This third band is still a strong indication of 
the presence of ER stress as splicing of XBP1 is occurring to produce this hybrid cDNA 
product. It was also described that XBP1h is most abundant during milder stresses, 








As we did not observe an increase in the ER stress response during thiopurine 
treatment, we suggest that thiopurines do not induce sufficient ER stress to initiate 
XBP1 splicing. ER stress signalling has been observed within the colonic and ileal 
mucosa of IBD patients, with an increase in grp78 and XBP1 expression within both 
inflamed and non-inflamed CD patient biopsies (Kaser et al., 2008; Shkoda et al., 
2007). Therefore, if thiopurines did cause ER stress in the cell, this could exacerbate 
the disease further. This indicates that thiopurines could assist in the removal of 
misfolded proteins in the cells by inducing the UPR independently of ER stress 
induction.  
 
Figure 39 - XBP1 variants observed during End-point PCR. 
Author’s adaptation of an illustration by Chalmer et al., (2017). The XBP1 hybrid variant is 
produced during the final step of the PCR process in which a single stand of spliced XBP1 and 
a single strand of unspliced XBP1 anneal together to form a larger cDNA structure that migrate 







6.10. Induction of the UPR by thiopurines 
The highest level of autophagy activity in response to thiopurines was observed at the 
8h timepoint, therefore, this timepoint was selected to investigate UPR activity in 
thiopurine treated THP-1 macrophages. Results demonstrated that, at the 8h time 
point, expression of genes downstream of PERK, such as ATF4 and CHOP, were 
upregulated during 6-TG treatment. An increase in the phosphorylation of eif2α was 
also observed during 6-TG treatment, indicating the activation of the PERK pathway. 
However, PERK did not show an increase in gene expression at the 8h time point. 
Hooper et al., 2019 observed an increase in PERK gene expression at the 6h time 
point during AZA treatment, which began to decrease after 24h. Therefore, use of an 
8h time point in our study may have resulted in an inability to quantify any increase in 
PERK gene expression, which appears to occur at an earlier time point (Hooper et al., 
2019). Interestingly, studies in other cell types have identified the regulation of PERK 
has been closely associated with effects in proliferation. Liu et al., (2019) 
demonstrated that down-regulation of PERK through shRNA reduced the proliferation 
of Lgr5+ cells in mice, a marker for intestinal stem cells. PERK has also been found to 
regulate proliferation in β cells and T47D breast cancer cells (Bobrovnikova-Marjon et 
al., 2010; Zhang et al., 2006). Therefore, the induction of PERK observed during 6-TG 
treatment may be a response to the reduction in proliferation potentially caused by 
MMR processing. 
6.11. Role of thiopurines and UPR in mitochondrial 
homeostasis 
PERK may be induced during thiopurine treatment to protect the cells from oxidative 
stress; and consequently, induces autophagy as one of its protective mechanisms. 
During the presence of cellular stress, it is critical that mitochondrial proteostasis is 
maintained. PERK has been found to manipulate pathways involved in protein import, 
folding and proteolysis to protect the mitochondrial proteome (Rainbolt et al., 2014). 
Therefore, PERK could be induced to protect the mitochondria from ROS-associated 
oxidative damage during thiopurine treatment. PERK has been found to regulate ROS 
production. Amodio et al. (2019) illustrated in PARK20 fibroblasts that inhibition of the 
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PERK/eif2α/ATF4 pathway through GSK2606414 treatment, a PERK inhibitor, 
significantly induced ROS production. PERK has also been found to be a critical 
component within MAMs acting as functional tether between the mitochondria and ER 
(Verfaillie et al., 2012). It was discovered that PERK regulates ROS-induced cell death 
through MAMs and that it’s structural function within MAMs was crucial in the induction 
of apoptosis, rather than its functional role in the UPR (Verfaillie et al., 2012). This 
hypothesis was formed as the loss of PERK resulted in severe structure changes 
within ER-mitochondria juxtapositions, and CHOP deficiency did not attenuate ROS 
associated apoptosis (Verfaillie et al., 2012). Therefore, the activation of PERK in 
response to mitochondrial injury and ROS accumulation could result in the activation 
of autophagy. 
PERK can induce autophagy through a number of different mechanisms. We observed 
an increase in ATF4 and CHOP expression during 6-TG treatment, as previously 
discussed, ATF4 and CHOP have been found to activate autophagy genes p62, 
Atg16L1 and Map1lc3B (B’Chir et al., 2013). The early apoptotic signalling observed 
through the staining of phosphatidylserine can also be initiated through this cascade, 
as CHOP is a well-defined inducer of pro-apoptotic genes, including the expression of 
two BH3-only pro-apoptotic Bcl-2 members, Bim and Puma (McQuiston and Diehl, 
2017). Therefore, the induction of PERK/eif2α signalling may initiate apoptotic 
signalling through CHOP, which activates autophagy as a counter measure to 
maintain cell survival. The activation of MMR processing by thiopurines may also 
induce the UPR, as cellular energy is critical for correct protein folding and post-
translation modifications of proteins in the ER (Bobrovnikova-Marjon et al., 2010).  It 
has also been identified PERK can induce the AMPK/mTORC1 pathway during ECM 
detachment in which cells are exposed to ER stress conditions (Avivar-Valderas et al., 
2011). Although this was only identified in endothelial cells, it illustrates a direct link 
between PERK and AMPK. Both PERK and AMPK have been found to be induced 
during AZA treatment, therefore it could be speculated that PERK modulates AMPK 
activity to induce autophagy. In addition, PERK has also been shown to upregulate 
the transcription of the E3 ligase, Parkin, in an ATG4 dependent manner to maintain 
mitochondrial turnover (Rainbolt et al., 2014). As increased expression of Parkin has 
been associated with the induction of mitophagy, it could suggest the induction of 




6.12. Regulation of mTORC1 signalling by thiopurines 
mTORC1 signalling is a critical regulatory pathway in autophagy activity, which 
functions to inhibit autophagy in the presence of nutrient sufficiency. We observed a 
reduction in the phosphorylation of rpS6 during AZA treatment compared to 6-MP and 
6-TG treatment, indicating that AZA inhibits mTORC1 signalling. This correlates with 
findings by Hooper et al., (2019) who also observed an inhibition of mTORC1 
signalling in AZA treated THP-1 derived macrophages. However, Hooper et al., (2019) 
did not investigate mTORC1 activity during 6-MP and 6-TG treatment. Our results 
contradict findings by other studies which demonstrated that 6-MP strongly inhibits 
mTORC1 signalling (Fernández-Ramos et al., 2017; Huang et al., 2016). However, an 
explanation for this could be that earlier timepoints were investigated within our study 
compared to Fernandez Ramos et al., (2017), who observed a statistically significant 
difference at the 24-48h timepoint. 
PERK has been found to regulate pro-survival and apoptotic signalling through 
mTORC1 signalling. ATF4 signalling regulates the expression of Sestrin2 and DNA 
damage and development 1 (REDD1), both of which have been found to inhibit 
mTORC1 signalling (McQuiston and Diehl, 2017). In addition, PERK mediates the 
production of phosphatidic acid due to its intrinsic lipid kinase activity, which 
subsequently can regulate mTORC1 formation and Akt phosphorylation 
(Bobrovnikova-Marjon et al., 2012; Toschi et al., 2009). AZA-induced autophagy 
activity was also suppressed by PERK inhibition, indicating that autophagy is in part 
induced by the PERK pathway (Hooper et al., 2019). However, Hooper et al., (2019) 
illustrated that PERK inhibition did not alter mTORC1 signalling during AZA treatment, 
suggesting that PERK signalling is either downstream or parallel to mTORC1 
signalling. This mechanistic link has been characterised before in GI neuroendocrine 
cells lines, where it was observed that mTOR inhibitors induce PERK activation, which 
maintained cell viability (Freis et al., 2017). 
mTORC1 activity is also positively correlated with mitochondrial activity, and has been 
found to decrease the anabolic state in the cell to reduce ROS production while 
enhancing autophagy (López et al., 2019). mTORC1 signalling has been found to be 
activated through RAC1, a known target of thiopurines. RAC1 inhibition by thiopurines 
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resulted in restored mobility in DC’s that were autophagy deficient. mTORC1 activity, 
therefore, may function through the inhibition of RAC1 signalling (Wildenberg et al., 
2017).  The immunosuppressive effects of 6-TG were found to be associated with the 
interference of RAC1 protein function (Shin et al., 2016). However, our results suggest 
that 6-MP and 6-TG does not function through the mTORC1 pathway, as we did not 
observe a reduction in phosphorylated rpS6. Shin et al., (2016) observed the 
interference of RAC1 function after a 3-day treatment with 6-TG, suggesting that this 
response occurs at a later time-point. mTOR inhibitors could therefore be utilised to 
determine if PERK signalling is downstream of mTORC1 during AZA treatment. This 
would also aid in elucidating if 6-MP and 6-TG-induced autophagy is dependent on 
mTORC1 signalling or functions through independent mechanisms. AMPK signalling 
could also be investigated to determine if the regulation of mTORC1 signalling is due 
to the sensing of metabolic stress by AMPK.   
The catabolism of AZA to 6-MP may also induce mTORC1 signalling due to the 
depletion of cysteine and GSH in the cell. Cysteine is oxidised to form cystine where 
it is shuttled to mammalian cells and is critical for the biosynthesis of GSH (Yu and 
Long, 2016). As discussed previously, biogenic thiols, GSH and cysteine, are critical 
in the metabolism of AZA due to the COO(-), SH and NH(3)(+) groups within GSH and 
cysteine reacting with the C(5i) atom present on the imidazole ring of AZA (Hoffmann 
et al., 2001). This reaction consumes intracellular GSH and has led to implications in 
hepatocytes such as a decreased metabolic activity, and necrosis (Menor et al., 2004). 
Interestingly, the decrease in cysteine and GSH pools have been found to suppress 
mTORC1 signalling, and induce the integrated stress response, including eif2α 
phosphorylation, similar to the response observed within our study (Yu and Long, 
2016. However, GSH could not suppress mTORC1 signalling without also the 
deprivation of cystine, indicating that cystine pools regulate mTORC1 signalling (Yu 
and Long, 2016). This hypothesis is supported by the work of Menor et al., (2004), 
who found that treatment with N-acetyl-L-Cysteine played a protective role within the 
mitochondria of AZA treated-rat hepatocytes and completely abolished metabolic loss. 
This indicates that the inhibition of mTORC1 seen during AZA treatment could possibly 
be due to the initial reaction that occurs during the metabolism of AZA instead of via a 




6.13. Clinical Significance of Thiopurine-induced autophagy activity 
6.13.1. Personalised therapies in IBD patients 
Personalised medicine has become a target for healthcare professionals to reduce 
side effects found in patients and costs associated with failed treatment. Interestingly, 
the ATG16L1 T300A variant has been associated with an increased therapeutic effect 
of thiopurines (Wildenberg et al., 2017). Therefore, the enhanced therapeutic effect 
found in individuals harbouring the T300A variant may be due to thiopurines enhancing 
autophagy that is otherwise impaired. We observed that 6-TG was able to induce UPR 
signalling at the dose tested compared to AZA and 6-MP. As autophagy was also 
induced during 6-TG treatment, 6-TG may induce dysfunctional pathways more 
effectively that AZA and 6-MP, which could partially explain why 6-TG brings more 
therapeutic benefits than AZA clinically. It would be of use to compare the 
effectiveness of thiopurines, particularly 6-TG, in individuals harbouring variants 
associated with autophagy and the UPR pathway, and if their response the treatment 
is more effective than individuals that do not harbour these variants. This could help 
develop more appropriate treatment strategies that avoid unwanted side effects in 
patients. 
Thiopurines play a key role in maintaining long-term remission in IBD patients (Lim 
and Chua, 2018). The recommendation by the European Crohn’s and Colitis 
Organisation is that AZA and 6-MP should be administered at a daily dose of 2-3 mg/kg 
and 1-1.5 mg/kg respectively (Lim and Chua, 2018). However, the clinical use of 6-TG 
has been disputed. Daily dosage regimes when using 6-TG suggest not to exceed 
20mg/day per patient irrespective of body weight (Goel et al., 2015). The findings that 
6-TG is a more efficacious metabolite is supported by our findings that demonstrated 
6-TG altered metabolic activity compared to AZA and 6-MP when all were used at the 
same concentrations. The increased activity of 6-TG has led to its use in IBD being 
restricted due to its hepatotoxic potential and its association with the onset of nodular 
regenerative hyperplasia (NRH) (Petit et al., 2008). However, these cases of NRH 
during 6-TG treatment were thought to be dose-dependent (Ward et al., 2017). For 
example, no cases of NRH have been found in patients treated with 6-TG at 20mg/day 
(Goel et al., 2015). Our results illustrated that 6-TG was able to induce the UPR and 
autophagy at the dose and time studied, compared to AZA and 6-MP which did not. 
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Therefore 6-TG appears to be a more efficacious metabolite than AZA and 6-MP. 
Currently used dosage regimes for AZA and 6-MP only see a therapeutic effect after 
12-17 weeks of treatment (Lim and Chua, 2018). As 6-TG appears to be the most 
effective thiopurine at inducing signalling pathways that are impaired in IBD patients, 
6-TG could induce a therapeutic effect more rapidly than AZA and 6-MP in IBD 
patients. 
6.13.2. Use of combination therapy in IBD 
Patients suffering from severe CD will initially be treated with therapies such as 
Infliximab, an anti-TNFα agent, which will induce remission in patients, and thiopurines 
will subsequently be giving to the patient (Lim and Chua, 2018). However, this drug 
regime has been placed under scrutiny in the past, as combination therapy has been 
proven to be more successful. For example, an open randomised trial found that a 
monotherapy approach only maintained steroid free remission in 35.9% of patients 
after 26 weeks compared to combination therapy, in which 60% of patients were 
maintained in steroid-free remission (D’Haens et al., 2008). Therefore, there is a need 
to find therapies that can be applied in combination without unwanted side effects. As 
we observed that thiopurines are able to activate autophagy activity, thiopurines could 
be used in combination with other known inducers of autophagy, including mTOR 
inhibitors such as Sirolimus (rapamycin), which has been found to be therapeutic in 
refractory CD (Massey et al., 2008). Thiopurines could also be used in conjunction 
with drugs known to alleviate ER stress. These include Tauroursodeoxycholic acid, 
which has been found to reduce ER stress and enhance protein folding in the liver of 
obese patients (Ma et al., 2017). These therapies in combination may induce 
dysfunctional pathway in patients that are genetically dispositioned and help maintain 
remission for longer. 
6.13.3. Clinical impact of TPMT activity in autophagy activity  
We observed that differences in cell types affect the rate at which autophagy is 
activated. Based upon previous findings, enzyme activity impacts the rate at which 
thiopurines are metabolised into its efficacious substrate (Chang and Cheon, 2019). 
TPMT is the most well documented enzyme associated with thiopurine metabolism 
and is largely considered the enzyme responsible for the variation in efficacy and 
toxicity in patients. The prevalence of genetic polymorphisms in TPMT is significant in 
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the population. 0.3% of the population are homozygous for absent TPMT activity, 10% 
are heterozygous for TPMT that produces intermediate activity and the polymorphisms 
that remain results in extensive TPMT activity in individuals (Kapur and Hanauer, 
2019). Individuals expressing polymorphisms that result in no TPMT activity will have 
an inability to inactivate thiopurines, resulting in a preference for thiopurines to be 
converted to 6-TGN by HPRT. This can result in standardised dosing of AZA and 6-
MP causing severe myelosuppression and, in some cases, can be life threatening 
(Chisick et al., 2013). In contrast, individuals with significantly higher TPMT enzyme 
activity will produce higher concentrations of inactive and hepatotoxic metabolites, 
such as 6-MMP, which can result in increased side effects. Both active and inactive 
metabolites produced by the enzymatic breakdown of thiopurines may have an impact 
on autophagy activation. Therefore, differences in TPMT enzyme activity found in 
patients may impact the rate at which autophagy is activated and therefore effect the 
efficacy of the drug. This reinforces the need for targeted therapeutic approaches 
when utilising thiopurines. 
6.14. Future Research  
6.14.1. ATF6 signalling in response to thiopurines 
As PERK was not observed to be induced at the timepoint investigated in our study, 
it’s beneficial to investigate further timepoints to characterise if the activation of PERK 
occurs at an earlier time point. ATF6 signalling was not characterised during our study 
due to the time constraints in investigating antibodies for ATF6. The ATF6 axis heavily 
contributes to the output found within the IRE1 axis, with ATF6 inducing the expression 
of BiP, XBP1 and EDEM1 (Hillary and Fitzgerald, 2018). Therefore, it would appear 
from the results found in our study that the ATF6 axis is not induced during thiopurine 
treatment. This could be confirmed with the use of an antibody that can detect the 
90kDa type II transmembrane glycoprotein form of ATF6 and the 50kDa amino-
terminal fragment of ATF6, which is cleaved as a result of the presence of ER stress 
(Hillary and FitzGerald, 2018). 
6.14.2. mTORC1 signalling in response to thiopurines 
We did not observe the regulation of mTORC1 signalling during 6-MP or 6-TG 
treatment at the 8h time point, however, 6-MP has been found to inhibit mTORC1 
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signalling during the 24-48h time point. Therefore, it would be of interest to explore the 
later timepoints from what was investigated in this study to conclude if the regulation 
of mTORC1 is solely seen in AZA treatment compared to 6-MP and 6-TG. mTORC1 
inhibitors also should be utilised to determine if mTORC1 regulates induced autophagy 
activity in AZA, 6-MP and 6-TG. PERK signalling should also be characterised during 
mTORC1 inhibition to determine if mTORC1 signalling functions upstream of PERK. 
6.14.3. Further assessment of autophagy signalling 
We illustrated, using a GFP-RFP-LC3 plasmid, that autophagy is induced during 
thiopurine treatment. However, it is advised when assessing autophagy activity to 
utilise at least two separate methodologies. Therefore, further investigations should 
confirm autophagy induction we observed within this study, preferably using a time-
course to compare the induction of autophagy between all thiopurines. Investigating 
p62 turnover through western blotting is an alternative method that can be utilised to 
monitor autophagy activity. p62 is involved in the shuttling of cargo proteins to the 
interior of autophagosomes, where it anchors to LC3 through LC3 interacting regions 
and is degraded and thus p62 is inversely correlated with autophagy activity (Yoshii 
and Mizushima, 2017). In addition, the activation of autophagy could be determined 
through the use of flow cytometry, in which the fluorescence of autophagosome 
associated LC3-II is quantified using the detergent saponin, which selects LC3-II 
through the removal of non-autophagosome specific LC3-I (Eng et al., 2010). 
6.14.4. Therapeutic effect of imidazole derivatives 
It was demonstrated that AZA induced autophagosome accumulation more rapidly 
than 6-MP or 6-TG. As this result was only performed once, it should be repeated to 
confirm the observation. Limited studies have investigated the therapeutic effect of the 
imidazole derivative which is produced during the catabolism of AZA. Studies indicate 
that the imidazole derivative may produce a potentially toxic effect as three quarters 
of patients who are intolerant to AZA treatment can tolerate 6-MP, with the only 
structural difference between the molecular structure between AZA and 6-MP being 
the imidazole derivative. However, this intolerance observed may be due to GSH 
depletion or excessive ROS production. In addition, in vitro studies have shown the 
imidazole derivative found on AZA can regulate immune activity (McGovern et al., 
2002). Additional studies should be conducted to analyse the immunomodulatory 
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properties of the imidazole derivative released during thiopurine treatment. If It is found 
that the imidazole derivative produces a therapeutic effect by stimulating autophagy 
activity, imidazole could be used as an alternative therapy to AZA, avoiding the 
unwanted side effects. 
6.14.5. Future use of in vitro and ex vivo models for IBD 
Leukaemia-derived THP-1 derived macrophages were used in this study to investigate 
macrophage response in response to thiopurine treatment. Cancerous human cell 
lines are an essential in vitro tools utilised to investigate pathways, mechanisms and 
responses. They also possess a level of reliability due to their homogenous genetic 
nature, which reduces the level of variability that is found when acquiring PBMC-
derived monocytes from blood donors. However, they also contain several drawbacks. 
For example, due to their malignant background and the culturing of these cell lines 
from outside their natural environment, these cell lines can become over-sensitised to 
various stimuli. This effect will portray mild responses to be much more significant. An 
example of this includes the excessive ROS production observed during 6-MP and 6-
TG treatment that is mainly restricted to tumour cell lines (Chaabane and Appell, 
2016). It is therefore suggested to perform an ex vivo study with a more clinically 
appropriate cell model, such as PBMC-derived macrophages. Selecting PBMC-
derived macrophages from patients with known CD-associated SNP’s could also be 
used to investigate the impact of these drugs on the induction of autophagy in these 
cells. 
Many IBD-associated studies have identified intestinal epithelial barrier dysfunction as 
a major contributing factor to intestinal inflammation. Adolph et al., (2013), presented 
evidence illustrating that Paneth cell dysfunction was the origin of intestinal 
inflammation in CD. As we observed differences in autophagy activity by thiopurines 
in different cell lineages, it would be important in future research to investigate the 
effect of thiopurines in intestinal cell lines. However, Paneth cells have been shown to 
have high sensitivity to increased ER stress inside the cell, which is indicated by 
studies showing deletion of XBP1 leads to defects in Paneth cells in the small intestine 
(Kaser et al., 2008).  Therefore, it may be beneficial to utilise a mouse model similar 
to the methodology used by Adolf et al., (2013,), which involved generating a XBP1-/- 
mouse model through tamoxifen treatment or selective deletion of ATG16L1 through 
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Cre-Lox recombination. Intestinal Crypts within the mice model could then be 
sectioned an analysed using immunofluorescent and histological techniques. This 
would allow us to analyse the effect of thiopurines on Paneth cell lineages in a mice 
model that resembles patients harbouring CD-associated SNPs. If, thiopurines can 
activate autophagy in IEC’s and prevent integrity breakdown, it could help explain why 
thiopurines are effective in maintaining long-term remission in IBD patients. 
6.14.6 Thiopurine induced mitochondrial dysfunction  
As many studies have reported the loss of mitochondria function during thiopurine 
treatment, it would be beneficial to explore mitochondria function and its association 
with the UPR and autophagy activity. An example of this could be using lipophilic 
cationic fluorescent dyes which can be used to assess mitochondrial membrane 
potential. As PERK is closely associated with MAMs found on the mitochondria, this 
could help elucidate if mitochondrial events are the cause of PERK induction. ROS 
produced during mitochondrial permeabilization has also been found to regulate 
autophagy and apoptotic signalling. Chaabane and Appell, (2016) found that ROS 
scavenging, utilising NAC, reduced both autophagy marker, LC3-II, and apoptosis in 
the cell. It would be of interest to determine if ROS scavenging regulates PERK and 
mTORC1 signalling during thiopurine treatment or if these pathways act independently 
of ROS production. The regulation of ROS and autophagy by PERK could also be 
characterised through the inhibition of PERK and observing ROS toxicity and 
autophagy activity in the cell.     
6.15. Conclusion 
We have demonstrated that thiopurines, AZA, 6-MP and 6-TG are all inducers of 
autophagy in THP-1 derived macrophages. As autophagy dysfunction leads to 
bacterial persistency in macrophages during IBD pathogenesis, the induction of 
autophagy by thiopurines may partially explain the therapeutic nature of the drug. Our 
results indicated that 6-TG is a more potent pro-drug compared to AZA and 6-MP, and 
6-TG induced downstream signalling of the UPR pathway, which could be therapeutic 
in CD patients that have been found to have elevated ER stress. We also observed 
an inhibition of mTORC1 signalling during AZA treatment, indicating the possibility of 
an independent mechanism of action for autophagy induction compared to 6-MP and 
6-TG. Due to the multifactorial nature of the disease and the underlying risk factors 
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that are uniquely found within each patient, there is a need to develop personalised 
treatments for IBD patients. The findings shown in this study help elucidate a part of 
the mechanism of action of thiopurines and could lead to more appropriate dosage 
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